T-Cell Immunotherapy Market (3rd Edition), 2018-2030

  • ID: 4557097
  • Report
  • 850 Pages
  • Roots Analysis
1 of 6

FEATURED COMPANIES

  • Abramson Cancer Center
  • Broadfin Capital
  • Flagship Pioneering
  • Lifeline Ventures
  • PolyBioCept
  • Target ALS Foundation
  • MORE

Cancer is known to be one of the leading causes of death worldwide, accounting for 0.6 million deaths in 2017 in the US alone. The World Health Organization states that the number of new cancer cases globally is expected to rise by 70% in the coming 20 years. Although cancer therapeutics continue to be one of the most active areas in terms of drug development, there is still a significant unmet need in this domain. Conventional cancer treatments, such as chemotherapy, surgery and radiation therapy, have demonstrated very limited efficacy in late-stage cancers. Specifically, chemotherapy and radiation therapy are also associated with several side effects. Their non-specific nature has severe detrimental effects on the patients’ quality of life.

Amidst the current initiatives to develop more targeted anti-cancer therapies, immunotherapy has emerged as a highly potent option to eradicate tumor cells with minimal side effects. It is based on the principle of harnessing the innate potential of the immune system to target and destroy diseased cells. It encompasses several treatment approaches, such as monoclonal antibodies, immune checkpoint inhibitors, therapeutic vaccines, cytokine therapies and cell-based therapies. In recent years, adoptive T-cell therapy (ACT) has emerged as a potent and viable therapeutic intervention. There are certain key characteristics that render T-cells suitable for use as effective therapeutic tools; these include target specificity, adaptability and the capability to retain immunologic memory.

Close to 120 academic and research institutes across the globe have made significant contributions to this field, mostly by convening the initial research on potential product candidates. These efforts have built the intellectual framework for the establishment of several start-ups; in fact, during the last five years, over USD 8 billion has been invested by VC firms/other strategic investors. It is also worth highlighting that there have been more than 200 instances of collaborations between industry/academic stakeholders. The ongoing innovation has also led to the discovery of several novel molecular targets, strengthening the research pipelines of various companies engaged in this domain. Encouraged by the recent approval of two CAR-T therapies, namely Kymriah® (Novartis) and Yescarta® (Gilead Sciences), and a robust development pipeline, the T-cell immunotherapy market offers considerable promise to a number of industry stakeholders.

The "T-Cell Immunotherapy Market, 2018-2030 (3rd edition)" report features an extensive study of the current market landscape and the future potential of T-cell immunotherapies (focusing particularly on CAR-T therapies, TCR therapies and TIL therapies). One of the key objectives of the study was to review and quantify the future opportunities associated with the ongoing development programs of both small and big pharmaceutical firms.

Amongst other elements, the report features the following:

  • An analysis depicting prevalent and emerging trends related to T-cell immunotherapies as observed on the social media platform, Twitter. In addition to the yearly chatter trends, the analysis highlights the most frequently talked about product candidates.
  • A detailed assessment of the current market landscape of T-cell immunotherapies with respect to type of therapies, type of developer (industry/non-industry), phase of development, target therapeutic indications, key target antigens, source of T-cells (autologous and allogenic), and route of administration. In addition, we have provided an overview of the competitive landscape, key challenges and anticipated future trends associated with T-cell based therapies.
  • Comprehensive profiles of marketed and mid to late stage clinical products (phase I/II or above); each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.
  • An analysis of the CAR constructs of clinical CAR-T therapies based on generation of CAR-T therapy (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of vector and type of co-stimulatory domain used.
  • An analysis of the global CAR-T clinical trials registered between 2009 and 2018, highlighting the year wise trend and the distribution across different geographies.
  • An overview of the various focus therapeutic areas of therapy developers, including an assessment of the opportunity offered by oncological and non-oncological disease indications.
  • A detailed discussion on innovative technology platforms that are being used for the development of T-cell therapies, along with profiles of key technology providers.
  • An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements and others.
  • An analysis of the investments that have been made into companies that have proprietary products/technologies, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing.
  • A case study on other T-cell based therapies, apart from CAR-Ts, TCRs and TILs. It presents a detailed analysis of the approved/pipeline products in this domain, including information on the current phase of development, target therapeutic areas, type of T-cells used, and source of T-cells.
  • A case study on manufacturing cell therapy products, highlighting the key challenges, and a list of contract service providers and in-house manufacturers that are involved in this space.
  • An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies. It features different models/approaches that a pharmaceutical company may choose to adopt to decide the price of a T-cell based immunotherapy that is likely to be marketed in the coming years.
  • A review of the key promotional strategies that have been adopted by the developers of the marketed T-cell therapies, namely Kymriah and Yescarta.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2018-2030. The report includes potential sales of T-cell immunotherapies that are currently marketed or are in late stages of development.

Additionally, the chapter presents a detailed market segmentation on the basis of type of therapy (CAR-T, TCR and TIL), geography (North America, Europe and Asia Pacific) and target indications (acute lymphoblastic leukemia, acute myeloid leukemia, bladder cancer, cervical carcinoma, chronic lymphocytic leukemia, esophageal cancer, head and neck cancer, multiple myeloma, hepatocellular carcinoma, melanoma, non-Hodgkin’s lymphoma, non-small cell lung cancer, ovarian cancer and synovial sarcoma). To account for the uncertainties associated with the development of these novel therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain.

The report features detailed transcripts of interviews held with the following individuals:

  • Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
  • Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys)
  • Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
  • Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)
  • Miguel Forte (Chief Operating Officer, TxCell)
  • Peter Ho (Director, Process Development, Iovance Biotherapeutics)
  • Tim Oldham (Chief Executive Officer, Cell Therapies)
  • Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR)
  • Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
  • Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital).

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights

  • Over 480 T-cell therapies are being developed across various preclinical/clinical stages. Amongst these, CAR-T cell products are the most common (75%), followed by TCR (18%) and TIL (7%) based therapies. Two CAR-T products, namely Kymriah® (Novartis) and YESCARTA® (Gilead Sciences), were approved in 2017 for the treatment of acute lymphoblastic leukemia and large B-cell lymphoma, respectively.
  • Around 63% of the pipeline therapies are undergoing clinical evaluation. Of the total clinical candidates, close to 40 therapies are in the late-stages of development (phase II and above) and are likely to enter the market in the next 5-10 years. Examples of late-stage therapies include bb2121 (bluebird bio/Celgene), IMCgp100 (Immunocore), MAGE A3 TCR (Kite Pharma), MB-CART19 (Miltenyi Biotec/Shanghai Children's Medical Center), NY-ESO-1 TCR (Adaptimmune Therapeutics/GSK), and LN-144 and LN-145 (Iovance Biotherapeutics).
  • More than 80% of the products in the development pipeline are presently being developed to treat various hematological cancers and solid tumors, including (in decreasing order of number of pipeline products) acute lymphoblastic leukemia (58), non-Hodgkin's lymphoma (51), multiple myeloma (38), melanoma (37), chronic lymphocytic leukemia (31), lung cancer (29), pancreatic cancer (25), acute myeloid leukemia (24), hepatocellular carcinoma (24), glioblastoma (21), breast cancer (20) and ovarian cancer (20). Several therapy candidates are being developed for other therapeutic areas, such as autoimmune disorders and infectious diseases, as well.
  • Amongst the various CAR-T therapies, 36% are designed to target the CD19 receptor. Other molecular targets that are being investigated include CD22, BCMA, Meso, CD20, GD2, CD30, HER1, HER2, EGFRvIII, MUC1, CD33, CD123, PSMA, GPC3, PD-L1, CEA, CD38, EPCAM and PSCA. Similarly, within the TCR segment, NY-ESO-1 is currently the most popular target antigen, followed by HBV, MART-1, p53, WT-1, MAGE A4, gp100, MAGE A3, HA-1 and MAGE A3/A6.
  • The market is highly fragmented and characterized by the presence of over 115 start-ups, small pharma and big pharma firms. The key players involved in development of T-cell therapies (based on the number of candidate therapies in their respective pipelines) include Shanghai GeneChem, Juno Therapeutics, Kite Pharma, Marino Biotechnology, Cellular Biomedicine Group, Iovance Biotherapeutics, Adaptimmune Therapeutics, CARsgen Therapeutics, The Beijing Pregene Science and Technology Company, Merck, Intrexon, Shanghai Unicar-Therapy Bio-medicine Technology, Takara Bio and ZIOPHARM Oncology.
  • Academic institutions are leading the innovation in this domain; many universities and research institutes have played a critical role in the discovery, design and development of novel CAR-T, TCR and TIL based therapies. Currently, around 55% of the pipeline therapies are being developed by academic players, either alone or in collaboration with industry players. The most active non-industry players (based upon the number of therapies under development) include the National Cancer Institute, Baylor College of Medicine, Shenzhen Geno-immune Medical Institute, University of Pennsylvania, Southwest Hospital, Chinese PLA General Hospital, Sun Yat-sen University, Fuda Cancer Hospital, Memorial Sloan Kettering Cancer Center, Peking University, Fred Hutchinson Cancer Research Center, Xinqiao Hospital of Chongqing, MD Anderson Cancer Center, and City of Hope Medical Center.
  • In order to exploit the commercial potential of their respective assets, stakeholders in the industry have forged several synergistic partnerships. Overall, we identified 200 partnerships between various players (industry and academia) in the period January 2005-January 2018. Approximately 23% of the deals were R&D agreements. Other popular types of collaborations that were established in this domain include technology licensing agreements (18%), product development and commercialization agreements (16%), manufacturing agreements (9%), acquisitions (7%), clinical trial agreements (7%) and product licensing agreements (6%).
  • Numerous contract manufacturing organizations (CMOs) with advanced capabilities have also emerged, offering services for manufacturing personalized T-cell based therapies. Examples of such CMOs include (in alphabetical order) Amsterdam Biotherapeutics Unit (AmBTU), apceth Biopharma, Atlantic Bio GMP, Brammer Bio, Cell and Gene Therapy Catapult, Cell Therapies, Cellular Therapeutics, EUFETS, MEDINET, MolMed, PCT, KBI Biopharma and WuXi AppTec.
  • More than 150 funding instances, amounting to more than USD 8 billion worth of capital investment, have taken place in this field over the past few years. Venture capital investments contribute to over 29% of the total funding received by companies that are focused in this field. This is followed by other types of equity investments (24%), IPOs and post-IPO equity (16%), and grants (13%). Several big-ticket investments have recently taken place. For instance, Gilead Sciences announced acquisition of Kite Pharma for about USD 11.9 billion in August 2017 and Celgene acquired Juno Therapeutics in a deal valued at about USD 9 billion in March 2018.
  • A variety of other types of T-cell immunotherapies, other than CAR-T, TCR and TIL, are also expected to emerge in the mid-long term. These include T-regulatory cell-based therapies, T-cell based vaccines, virus-driven T-cell therapies and next generation ?d immunotherapies. Companies such as TxCell, Caladrius Biosciences, Casebia Therapeutics, Cellenkos, Miltenyi Biotec, TRACT Therapeutics and Tmunity Therapeutics, are developing T-regulatory cell based therapies. Other players, namely Acer Therapeutics, Immunovative Therapies and TVAX Biomedical, are developing T-cell based vaccines for treating autoimmune disorders and various forms of cancer. Further, Atara Biotherapeutics, bluebird bio, Cell Medica, Shanghai iCELL Biotechnology and Tessa Therapeutics are working on the development of virus-driven T-cell therapies. Additionally, GammaCell Bio-Technologies is developing next generation ?d immunotherapies against various oncological indications, infectious diseases and autoimmune disorders.
  • The T-cell immunotherapy market is projected to grow at an annualized rate of over 80% during the time period 2018-2030. Specifically, by 2030, close to 61% of the market is likely to be driven by CAR-T therapies. The market, in the long term, is likely to be driven by five indications, namely non-Hodgkin’s lymphoma (45%), bladder cancer (13%), melanoma (11%), acute lymphoblastic leukemia (7%) and multiple myeloma (7%). Product candidates, such as Kymriah®, Yescarta®, JCAR017, ALT 801, NY-ESO-1 TCR and IMCgp100 are expected to achieve blockbuster status.
  • In terms of geographical distribution, North America is the current hub and is likely to continue to dominate the market in the next decade. However, there is a general perception that, owing to the fact that more than 60% of the CAR-T trials are currently being conducted in China, the country is likely to grow at a relatively faster rate as compared to the developed regions.
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Abramson Cancer Center
  • Broadfin Capital
  • Flagship Pioneering
  • Lifeline Ventures
  • PolyBioCept
  • Target ALS Foundation
  • MORE

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Immunotherapy, an Emerging Therapeutic Option
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.1.1. Active Immunotherapy
3.5.1.2. Passive Immunotherapy
3.5.2. By Type of Target
3.5.3. By Approach
3.5.4. By Product Class
3.5.4.1. Monoclonal Antibodies
3.5.4.2. Bispecific Antibodies
3.5.4.3. Cytokines
3.5.4.4. Oncolytic Virus Therapy
3.5.4.5. Therapeutic Cancer Vaccines
3.5.4.6. Cell-based Therapies
3.6. Historical Evolution of T-Cell Immunotherapies
3.7. Key Considerations of T-Cell Immunotherapies
3.8. Strategies Employed for Redirection of T-Cells
3.9. Manufacturing of Engineered T-Cells
3.10. T-Cell Transduction/Transfection Methods
3.10.1. Retroviral Vectors
3.10.2. Lentiviral Vectors
3.10.3. Non-viral Transfection Methods
3.11. Therapeutic Areas Targeted by T-Cell Immunotherapies
3.12. Key Challenges of T-Cell Immunotherapies

4. EMERGING TRENDS ON SOCIAL MEDIA
4.1. Chapter Overview
4.2. Trends on Twitter
4.2.1. T-Cell Immunotherapies: Yearly Trends on Twitter
4.2.2. T-Cell Immunotherapies: Popular Keywords on Twitter
4.2.3. T-Cell Immunotherapies: Most Popular Drugs on Twitter

5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. T-Cell Immunotherapies: A Promising Pipeline
5.2.1. T-Cell Immunotherapies: Distribution by Type of Product
5.2.2. T-Cell Immunotherapies: Distribution by Type of Developer
5.2.3. T-Cell Immunotherapies: Distribution by Phase of Development
5.2.4. T-Cell Immunotherapies: Target Oncological Indications
5.2.4.1. CAR-T Immunotherapies: Popular Target Indications
5.2.4.2. TCR Immunotherapies: Popular Target Indications
5.2.4.3. TIL Immunotherapies: Popular Target Indications
5.3.5. T-Cell Immunotherapies: Popular Target Antigens for CAR-T and TCR Therapies
5.3.6. T-Cell Immunotherapies: Distribution by Source of T-Cells
5.3.7. T-Cell Immunotherapies: Distribution by Route of Administration
5.3.8. T-Cell Immunotherapies: Key Industry Players
5.3.9. T-Cell Immunotherapies: Key Non-Industry Players

6. KEY INSIGHTS
6.1. Chapter Overview
6.2. T-Cell Immunotherapies: Analysis by Popularity of Target Antigens
6.2.1. Hematological Cancer: Popular Targets
6.2.1.1. CD19 CAR-T Immunotherapies: Competitive Landscape
6.2.1.2. CD19 CAR-T Immunotherapies: Clinical Trial Results of Prominent Product Candidates
6.2.1.3. BCMA CAR-T Immunotherapies: Competitive Landscape
6.2.1.4. BCMA CAR-T Immunotherapies: Clinical Trial Results of Prominent Product Candidates
6.2.2. Solid Tumors: Popular Targets
6.2.2.1. Meso CAR-T Immunotherapies: Competitive Landscape
6.2.2.2. Meso CAR-T Immunotherapies: Clinical Trial Results of Prominent Product Candidates
6.2.2.3. GD2 CAR-T Immunotherapies: Competitive Landscape
6.2.2.4. GD2 CAR-T Immunotherapies: Clinical Trial Results of Prominent Product Therapies
6.3. T-Cell Immunotherapies: CAR-T Clinical Trial Trends, Pre-2012-2018
6.3.1. Analysis by Trial Registration Year
6.3.2. Geographical Analysis by Number of Registered Trials
6.4. T-Cell Immunotherapies: Clinical Trial Overview
6.4.1. Clinical Trial Analysis: Distribution by Type of Product
6.4.2. Clinical Trial Analysis: Distribution by Phase of Development
6.4.3. Clinical Trial Analysis: Distribution by Patient Segment
6.4.4. Clinical Trial Analysis: Distribution by Type of Therapy

7. CHIMERIC ANTIGEN RECEPTOR-T CELL THERAPY
7.1. Introduction
7.2. History of Development
7.3. Key Opinion Leaders
7.4. Anatomical Layout of Chimeric Antigen Receptor
7.5. CAR-T Construction Analysis
7.5.1. Analysis by Generation of CAR-T Therapies
7.5.2. Analysis by Type of scFv Antibody
7.5.3. Analysis by Type of Vector
7.5.4. Analysis by Type of Co-Stimulatory Domain(s)
7.6. Development of Chimeric Antigen Receptors
7.7. Development of CAR-T Cells
7.8. Universal CAR-Ts
7.9. Route of Administration
7.10. Toxicity Concerns
7.10.1. Cytokine Release Syndrome (CRS)
7.10.2. On-Target Off-Target Toxicity
7.10.3. Encephalopathy and B-Cell Aplasia
7.10.4. Neurological Toxicity
7.10.5. Anaphylaxis
7.10.6. Insertional Oncogenesis
7.10.7. Graft Versus Host Disease (GVHD)
7.11. Management of Toxicity Issues
7.11.1. Pharmacological Immunosuppression
7.11.2. Target Selection
7.11.3. Cell Persistence
7.11.4. Elimination Genes
7.11.5. Receptor Expression
7.12. CD19: An Attractive Target
7.13. Other Targets
7.14. Challenges Associated with CAR-T Therapies
7.14.1. Competitive Risks
7.14.2. Clinical Risks
7.14.3. Regulatory Risks
7.14.4. Commercial Risks
7.15. Kymriah®/Tisagenlecleucel/CTL019 (Novartis)
7.15.1. Therapy Overview
7.15.2. History of Development
7.15.3. Current Development Status
7.15.4. Key Clinical Trial Results
7.15.5. Dosage Regimen, Price and Manufacturing
7.16. Yescarta®/Axicabtagene Ciloleucel/KTE-C19 (Kite Pharma)
7.16.1. Therapy Overview
7.16.2. Current Development Status
7.16.3. Key Clinical Trial Results
7.16.4. Dosage Regimen, Price and Manufacturing
7.16.5. Next Generation eACT CAR Candidates
7.17. JCAR (Juno Therapeutics)
7.17.1. Therapy Overview
7.17.2. CAR-T Design
7.17.3. Current Development Status
7.17.4. Key Clinical Trial Results
7.17.4.1. JCAR014
7.17.4.2. JCAR017
7.17.4.3. JCAR018
7.17.5. Dosage Regimen and Manufacturing
7.18. CAR-T Series (Cellular Biomedicine Group)
7.18.1. Therapy Overview
7.18.2. History of Development
7.18.3. Current Development Status
7.18.4. Key Clinical Trial Results
7.18.4.1. CBM-EGFR.1
7.18.4.2. CBM-C19.1
7.18.4.1. CBM-C20.1
7.18.4.2. CBM-C30.1
7.18.5. Dosage Regimen and Manufacturing
7.18.6 Patent Portfolio
7.19. CD19 CAR (Takara Bio)
7.19.1. Therapy Overview
7.19.2. Current Development Status
7.19.3. Key Clinical Trial Results
7.19.4. Dosage Regimen and Manufacturing
7.20. Dual Targeting CAR-T Cell Therapies (Autolus)
7.20.1. Therapy Overview
7.20.2. Current Development Status
7.20.3. Key Clinical Trial Results
7.20.4. Dosage Regimen and Manufacturing
7.21. CAR-T Therapies (Sinobioway Cell Therapy/The First Affiliated Hospital of Anhui Medical University)
7.21.1. Therapy Overview
7.21.2. Current Development Status
7.21.3. Key Clinical Trial Results
7.21.4. Dosage Regimen and Manufacturing

8. T-CELL RECEPTOR (TCR) BASED THERAPIES
8.1. Chapter Overview
8.2. Structure of the T-Cell Receptor
8.3. Differences Between CAR and TCR
8.4. History of Development
8.5. Mechanism of Action
8.6. Key Opinion Leaders
8.7. Safety Concerns
8.7.1. Insertional Mutagenesis
8.7.2. On-Target, Off-Tumor Toxicity and Cross-Reactivity
8.7.3. TCR Mismatch Pairing
8.8. Prerequisites for Antigen-Specific T-Cell Receptors
8.9. Strategies to Enhance Antitumor Efficacy
8.9.1. Affinity Enhanced TCRs
8.9.2. Soluble TCR Based Biologics
8.10. SPEAR® T-Cells (Adaptimmune)
8.10.1. Therapy Overview
8.10.1.1. NY-ESO SPEAR T-Cell
8.10.1.2. Mage-A10 T-Cell Therapy
8.10.1.3. AFP T-Cell Therapy
8.10.1.4. Mage-A4 T-Cell Therapy
8.10.2. History of Development
8.10.3. SPEAR T-Cells Technology Platform
8.10.4. Current Development Status
8.10.5. Key Clinical Trial Results
8.10.6. Dosage Regimen and Manufacturing
8.11. ALT-801 (Altor BioScience)
8.11.1. Therapy Overview
8.11.2. History of Development
8.11.3. Current Development Status
8.11.4. Key Clinical Trial Results
8.11.5. Dosage Regimen
8.11.6. Patent Portfolio
8.12. IMCgp100 (Immunocore)
8.12.1. Therapy Overview
8.12.2. Current Development Status
8.12.3. Key Clinical Trial Results
8.12.4. Dosage Regimen and Manufacturing
8.13. JTCR016 (Juno Therapeutics)
8.13.1. Therapy Overview
8.13.2. Current Development Status
8.13.3. Key Clinical Results
8.13.4. Dosage Regimen
8.14. CMD-602/WT1 TCR Therapy (Cell Medica)
8.14.1. Therapy Overview
8.14.2. History of Development
8.14.3. Current Development Status
8.14.4. Key Clinical Trial Results
8.14.5. Dosage Regimen and Manufacturing
8.15. TBI-1301 (Takara Bio)
8.15.1. Therapy Overview
8.15.2. Current Development Status
8.15.3. Key Clinical Trial Results
8.15.4. Dosage Regimen and Manufacturing

9. TUMOR INFILTRATING LYMPHOCYTES (TIL) BASED THERAPIES
9.1. Chapter Overview
9.2. History of Development
9.3. Key Opinion Leaders
9.4. Strategies to Enhance Efficacy
9.5. Prognostic Applications
9.6. Manufacturing Process
9.7. Autologous TIL Therapies (Iovance Biotherapeutics)
9.7.1. Therapy Overview
9.7.2. Current Development Status
9.7.2.1. LN-144
9.7.2.2. LN-145
9.7.3. Key Clinical Trial Results
9.7.4. Dosage Regimen and Manufacturing
9.7.5. Patent Portfolio
9.8. TIL (Nantes University Hospital)
9.8.1. Therapy Overview
9.8.2. Current Development Status
9.8.3. Key Clinical Trial Results
9.8.4. Dosage Regimen and Manufacturing
9.9. TIL (Netherlands Cancer Institute)
9.9.1. Therapy Overview
9.9.2. Current Development Status
9.9.3. Key Clinical Trial Results
9.9.4. Dosage Regimen and Manufacturing

10. KEY THERAPEUTIC AREAS FOR T-CELL THERAPIES
10.1. Chapter Overview
10.2. Hematological Malignancies
10.2.1. Leukemia and Lymphoma
10.2.1.1. Leukemia: Introduction and Epidemiology
10.2.1.1.1. Acute Myeloid Leukemia (AML)
10.2.1.1.2. Chronic Myeloid Leukemia (CML)
10.2.1.1.3. Acute Lymphocytic Leukemia (ALL)
10.2.1.1.4. Chronic Lymphocytic Leukemia (CLL)
10.2.1.2. Lymphoma: Introduction and Epidemiology
10.2.1.3. Current Treatment Landscape
10.2.1.3.1. Targeted Therapies
10.2.1.4. T-Cell Immunotherapy and Research Landscape
10.2.1.4.1. CAR-T Therapies and Leukemia/Lymphoma
10.2.1.4.2. TCR Therapies and Leukemia/Lymphoma
10.2.2. Multiple Myeloma
10.2.2.1. Introduction and Epidemiology
10.2.2.2. Current Treatment Landscape
10.2.2.3. T-Cell Immunotherapy and Research Landscape
10.3. Solid Tumors
10.3.1. Metastatic Melanoma
10.3.1.1. Introduction and Epidemiology
10.3.1.2. Current Treatment Landscape
10.3.1.3. T-Cell Immunotherapy and Research Landscape
10.3.1.3.1. TILs and Metastatic Melanoma
10.3.1.3.2. TCRs and Metastatic Melanoma
10.3.1.3.3. CAR-Ts and Metastatic Melanoma
10.3.2. Lung Cancer
10.3.2.1. Introduction and Epidemiology
10.3.2.2. Current Treatment Landscape
10.3.2.3. T-Cell Immunotherapy and Research Landscape
10.3.3. Bladder Cancer
10.3.3.1. Introduction and Epidemiology
10.3.3.2. Current Treatment Landscape
10.3.3.3. T-Cell Immunotherapy and Research Landscape
10.3.4. Kidney Cancer
10.3.4.1. Introduction and Epidemiology
10.3.4.2. Current Treatment Landscape
10.3.4.3. T-Cell Immunotherapy and Research Landscape
10.3.5. Ovarian Cancer
10.3.5.1. Introduction and Epidemiology
10.3.5.2. Current Treatment Landscape
10.3.5.3. T-Cell Immunotherapy and Research Landscape
10.3.5.3.1. CAR-Ts and Ovarian Cancer
10.3.5.3.2. TCRs and Ovarian Cancer
10.3.5.3.3. TILs and Ovarian Cancer
10.3.6. Breast Cancer
10.3.6.1. Introduction and Epidemiology
10.3.6.2. Current Treatment Landscape
10.3.6.3. T-Cell Immunotherapy and Research Landscape
10.3.6.3.1. CAR-Ts and Breast Cancer
10.3.6.3.2. TILs and Breast Cancer

11. EMERGING TECHNOLOGIES
11.1. Chapter Overview
11.2. Genome Editing Technologies
11.2.1. Technology Overview
11.2.2. Applications
11.2.3. Emerging Technology Platforms used in T-Cell Therapies
11.2.3.1. CRISPR/Cas9 System
11.2.3.1.1. Key Components and Function
11.2.3.1.2. Mechanism of Action
11.2.3.1.3. Targeting Efficiency and Challenges
11.2.3.1.4. Next-GEN CRISPR Technology
11.2.3.1.5. Technology Providers
11.2.3.1.5.1. Editas Medicine
11.2.3.1.5.2. Intellia Therapeutics
11.2.3.1.5.3. CRISPR Therapeutics
11.2.3.2. TALENs
11.2.3.2.1. Key Components and Function
11.2.3.2.2. Mechanism of Action
11.2.3.2.3. Advantages and Challenges
11.2.3.2.4. Technology Providers
11.2.3.2.4.1. Cellectis
11.2.3.2.4.2. Editas Medicine
11.2.3.3. megaTAL
11.2.3.3.1. Technology Providers
11.2.3.3.1.1. bluebird bio
11.2.3.4. Zinc Finger Nuclease
11.2.3.4.1. Technology Providers
11.2.3.4.1.1. Sangamo Therapeutics
11.3. Designing T-Cell Therapies with Improved Characteristics
11.3.1. Technologies for Targeting Multiple Cancers
11.3.1.1. Antibody Coupled T-Cell Receptor (Unum Therapeutics)
11.3.1.2. NKR-T Platform (Celyad)
11.3.2. Technologies for Improved Safety
11.3.2.1. Armored CAR and EGFRt Technology (Juno Therapeutics)
11.3.2.2. RheoSwitch Therapeutic System (Intrexon)
11.3.2.3. Inducible Caspase 9 Safety Switch (Bellicum Pharmaceuticals)
11.3.2.3.1. CaspaCIDe Technology
11.3.2.3.2. CIDeCAR Technology
11.3.2.3.3. GoCAR-T Technology
11.3.2.4. On-Off Switch, Multiple Companies
11.3.2.4.1. Inhibitory CAR (iCAR) (Juno Therapeutics)
11.3.2.4.2. On-Off Switch (Theravectys)
11.3.2.5. Other Technologies to Improve CAR-T Safety
11.3.2.6. Allogeneic Technologies
11.3.2.6.1. CIK CAR-T Cells (Formula Pharmaceuticals)
11.3.2.6.2. Allogeneic Platform (Celyad)
11.3.2.6.3. Allogeneic Platform (Cellectis)

12. PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Types of Partnership Models
12.3. T-Cell Immunotherapy Market: Partnerships and Collaborations
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership Model
12.3.3. Analysis by Number of Partnerships (Most Active Industry Players)
12.3.4. Analysis by Number of Partnerships (Most Active Non-Industry Players)
12.3.5. Analysis by Type of Product
12.3.6. Analysis by Individual Products

13. FUNDING AND INVESTMENT ANALYSIS
13.1. Chapter Overview
13.2. Types of Funding
13.3. T-Cell Immunotherapy Market: Funding and Investment Analysis
13.3.1. Analysis by Number of Funding Instances
13.3.2. Analysis by Amount Invested
13.3.3. Analysis by Type of Funding
13.3.4. Analysis by Key Players

14. OTHER T-CELL IMMUNOTHERAPIES
14.1. Chapter Overview
14.2. Other T-Cell Immunotherapies
14.2.1. Distribution by Phase of Development
14.2.2. Distribution by Target Therapeutic Area
14.2.3. Distribution by Type of Cells
14.2.4. Distribution by Source of T-Cells
14.3. Treg Cell Therapy
14.3.1. Caladrius Biosciences
14.3.2. TxCell
14.3.3. TRACT Therapeutics
14.3.4. Cellenkos
14.3.5. Other Companies
14.4. T-Cell-based Vaccines
14.4.1. Immunovative Therapies
14.4.2. Acer Therapeutics
14.4.3. TVAX Biomedical
14.5. Virus-Driven T-Cell Therapies
14.5.1. Atara Biotherapeutics
14.5.2. Cell Medica
14.5.3. Tessa Therapeutics
14.6. Fucosylation Technology Platform
14.6.1. Targazyme
14.7. PD-1 Knockout Engineered T-Cell Therapy
14.7.1. Chengdu MedGenCell
14.7.2. Anhui Kedgene Biotechnology
14.7.3. Cell Biotech
14.8. TAC-T Cell Therapy
14.8.1. Triumvira
14.9. Gama Delta T-Cell Immunotherapy
14.9.1. GammaCell Bio-Technologies

15. CASE STUDY: CELL THERAPY MANUFACTURING
15.1. Chapter Overview
15.2. Introduction
15.3. Key Challenges
15.4. Current Trends
15.4.1. Companies with In-House Capabilities
15.4.2. Contract Manufacturers
15.5. Key Considerations for a Manufacturing Site
15.6. Regulatory Landscape

16. T-CELL IMMUNOTHERAPY: COST PRICE ANALYSIS
16.1. Chapter Overview
16.2. Factors Contributing Towards High Price Tags of Cell/Gene Therapies
16.3. Pricing Models for T-Cell Immunotherapies
16.3.1. On the Basis of Associated Costs
16.3.2. On the Basis of Competition
16.3.3. On the Basis of Patient Segment
16.3.4. On the Basis of Experts Opinions
16.4. Reimbursement Considerations for T-Cell Immunotherapies
16.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T Therapy

17. MARKET SIZING AND OPPORTUNITY ANALYSIS
17.1. Chapter Overview
17.2. Scope and Limitations
17.3. Forecast Methodology
17.4. Overall T-Cell Immunotherapy Market, 2018-2030
17.4.1. T-Cell Immunotherapy Market: Distribution by Type of Therapy
17.4.2. T-Cell Immunotherapy Market: Distribution by Geography
17.4.3. T-Cell Immunotherapy Market: Distribution by Target Indications
17.5. T-Cell Immunotherapy Market: Product-Wise Sales Forecasts
17.5.1. Overall CAR-T Therapy Market
17.5.1.1. Kymriah (Novartis)
17.5.1.1.1. Target Population
17.5.1.1.2. Sales Forecast
17.5.1.2. Yescarta (Gilead Sciences)
17.5.1.2.1. Target Population
17.5.1.2.2. Sales Forecast
17.5.1.3. CD19 CAR-T (Sinobioway Cell Therapy/The First Affiliated Hospital of Anhui Medical University)
17.5.1.3.1. Target Population
17.5.1.3.2. Sales Forecast
17.5.1.4. GPC3 CAR-T (Shanghai GeneChem)
17.5.1.4.1. Target Population
17.5.1.4.2. Sales Forecast
17.5.1.5. TBI-1501/CD19 CAR-T (Takara Bio/Jichi Medical University)
17.5.1.5.1. Target Population
17.5.1.5.2. Sales Forecast
17.5.1.6. JCAR017 (Juno Therapeutics/Celgene)
17.5.1.6.1. Target Population
17.5.1.6.2. Sales Forecast
17.5.1.7. MB-CART19.1 (Miltenyi Biotec/Shanghai Children's Medical Center)
17.5.1.7.1. Target Population
17.5.1.7.2. Sales Forecast
17.5.1.8. IM19 CAR-T (Beijing Immunochina Medical Science & Technology)
17.5.1.8.1. Target Population
17.5.1.8.2. Sales Forecast
17.5.1.9. PCAR-019 (PersonGen BioTherapeutics)
17.5.1.9.1. Target Population
17.5.1.9.2. Sales Forecast
17.5.1.10. AUTO2 (Autolus)
17.5.1.10.1. Target Population
17.5.1.10.2. Sales Forecast
17.5.1.11. AUTO3 (Autolus)
17.5.1.11.1. Target Population
17.5.1.11.2. Sales Forecast
17.5.1.12. BCMA CAR-T (The Beijing Pregene Science and Technology/Henan Cancer Hospital)
17.5.1.12.1. Target Population
17.5.1.12.2. Sales Forecast
17.5.1.13. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology/Henan Cancer Hospital)
17.5.1.13.1. Target Population
17.5.1.13.2. Sales Forecast
17.5.1.14. CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology/The First Affiliated Hospital of Soochow University)
17.5.1.14.1. Target Population
17.5.1.14.2. Sales Forecast
17.5.1.15. LCAR-B38M CAR-T (Nanjing Legend Biotech)
17.5.1.15.1. Target Population
17.5.1.15.2. Sales Forecast
17.5.1.16. CD19 CAR-T (Shanghai Bioray Laboratory)
17.5.1.16.1. Target Population
17.5.1.16.2. Sales Forecast
17.5.1.17. bb2121 (Celgene/bluebird bio)
17.5.1.17.1. Target Population
17.5.1.17.2. Sales Forecast
17.5.2. Overall TCR Therapy Market
17.5.2.1. IMCgp100 (Immunocore)
17.5.2.1.1. Target Population
17.5.2.1.2. Sales Forecast
17.5.2.2. NY-ESO-1 TCR (Adaptimmune/GSK)
17.5.2.2.1. Target Population
17.5.2.2.2. Sales Forecast
17.5.2.3. JTCR016 (Juno Therapeutics)
17.5.2.3.1. Target Population
17.5.2.3.2. Sales Forecast
17.5.2.4. LTCR-H1-2 (Lion TCR, Agency for Science, Technology and Research, Third Affiliated Hospital, Sun Yat-Sen University)
17.5.2.4.1. Target Population
17.5.2.4.2. Sales Forecast
17.5.2.5. ALT 801 (Altor Bioscience)
17.5.2.5.1. Target Population
17.5.2.5.2. Sales Forecast
17.5.2.6. TBI-1301 (Takara Bio)
17.5.2.6.1. Target Population
17.5.2.6.2. Sales Forecast
17.5.3. Overall TIL Therapy Market
17.5.3.1. TIL (Nantes University Hospital)
17.5.3.1.1. Target Population
17.5.3.1.2. Sales Forecast
17.5.3.2. TIL (Netherlands Cancer Institute)
17.5.3.2.1. Target Population
17.5.3.2.2. Sales Forecast
17.5.3.3. LN-144 (Iovance Biotherapeutics)
17.5.3.3.1. Target Population
17.5.3.3.2. Sales Forecast
17.5.3.4. LN-145 (Iovance Biotherapeutics)
17.5.3.4.1. Target Population
17.5.3.4.2. Sales Forecast

18. PROMOTIONAL ANALYSIS
18.1. Chapter Overview
18.2. Channels Used for Promotional Campaigns
18.3. Summary of Product Website Analysis
18.4. Summary of Patient Support Services and Informative Downloads
18.5. Kymriah®: Promotional Analysis
18.5.1. Drug Overview
18.5.2. Product Website Analysis
18.5.2.1. Messages for Healthcare Professionals
18.5.2.2. Messages for Patients
18.5.3. Patient Support Services and Informative Downloads
18.5.4. Other Promotional Activities
18.5.4.1. Presence in Conferences
18.6. Yescarta®: Promotional Analysis
18.6.1. Drug Overview
18.6.2. Product Website Analysis
18.6.2.1. Messages for Patients and Caregivers
18.6.2.2. Patient Support Services and Informative Downloads
18.6.3. Other Promotional Activities
18.6.3.1. Presence in Conferences

19. COMPANY PROFILES
19.1. Chapter Overview
19.2. Adaptimmune Therapeutics
19.3. Autolus
19.4. bluebird bio
19.5. CARsgen Therapeutics
19.6. Celgene
19.7. Cell Medica
19.8. Cellectis
19.9. Cellular Biomedicine Group
19.10. Immunocore
19.11. Innovative Cellular Therapeutics
19.12. Iovance Biotherapeutics
19.13. Kite Pharma (A Gilead Sciences Company)
19.14. Lion TCR
19.15. Novartis
19.16. Sinobioway Cell Therapy
19.17. Takara Bio
19.18. Unum Therapeutics
19.19. ZIOPHARM Oncology

20. CONCLUSION
20.1. With Steady Growth in the Development Pipeline, T-Cell based Therapies have Emerged as a Promising Segment of the Immunotherapy Market
20.2. Hematological Malignancies and Solid Tumors are Currently the Major Target Indications
20.3. The Competitive Landscape Features a Mix of Established Players and Start-ups, with Academic Institutes Spearheading Early-stage Development Activities
20.4. A Number of Novel Technology Platforms have also Emerged as Vital Enablers of Growth in this Market
20.5. Multiple Novel Types of Immunotherapies, other than CAR-T, TCR and TIL, are also Expected to Enter the Market in the Mid-Long Term
20.6. Increasing Partnership Activity and Financial Support from Various Investors are Indicative of the Lucrative Future Potential
20.7. The Premium Pricing of these Therapies Necessitate Appropriate Reimbursement and Promotional Strategies to Guarantee Commercial Success
20.8. Driven by the Approval of Two CAR-T Therapies and Encouraging Results of Late-stage Candidates, the Market is Expected to Grow Significantly in the Long Term

21. EXECUTIVE INSIGHTS
21.1. Chapter Overview
21.2. Cell Therapies
21.2.1. Company Snapshot
21.2.2. Interview Transcript: Tim Oldham, Chief Executive Officer
21.3. Celyad
21.3.1. Company Snapshot
21.3.2. Interview Transcript: Vincent Brichard, Vice President, Immuno-Oncology
21.4. Changhai Hospital
21.4.1. Company Snapshot
21.4.2. Interview Transcript: Xian-Bao Zhan, Professor of Medicine and Director, Department of Oncology
21.5. Iovance Biotherapeutics
21.5.1. Company Snapshot
21.5.2. Interview Transcript: Peter Ho, Director, Process Development
21.6. Kite Pharma
21.6.1. Company Snapshot
21.6.2. Interview Transcript: Adrian Bot, Vice President, Scientific Affairs
21.7. Lion TCR
21.7.1. Company Snapshot
21.7.2. Interview Transcript: Victor Lietao Li, Co-Founder and Chief Executive Officer
21.8. Theravectys
21.8.1. Company Snapshot
21.8.2. Interview Transcript: Aino Kalervo, Competitive Intelligence Manager, Strategy & Business Development
21.9. TxCell
21.9.1. Company Snapshot
21.9.2. Interview Transcript: Miguel Forte, Chief Operating Officer
21.10. University of Colorado
21.10.1. Company Snapshot
21.10.2. Interview Transcript: Enkhtsetseg Purev, Assistant Professor of Medicine
21.11. Waisman Biomanufacturing
21.11.1. Company Snapshot
21.1.2. Interview Transcript: Brian Dattilo, Manager of Business Development

22. APPENDIX 1: TABULATED DATA

23. APPENDIX 2: LIST OF COMPANIES

LIST OF TABLES
Table 3.1 Different Types of Immunotherapies and their Mechanism of Action
Table 5.1 T-Cell Immunotherapies: Clinical Pipeline
Table 5.2 T-Cell Immunotherapies: Preclinical Pipeline
Table 6.1 CD19 CAR-T Immunotherapies: Competitive Landscape
Table 6.2 CD19 CAR-T Immunotherapies: Clinical Outcomes
Table 6.3 BCMA CAR-T Immunotherapies: Competitive Landscape
Table 6.4 BCMA CAR-T Immunotherapies: Clinical Outcomes
Table 6.5 Meso CAR-T Immunotherapies: Competitive Landscape
Table 6.6 Meso CAR-T Immunotherapies: Clinical Outcomes
Table 6.7 GD2 CAR-T Immunotherapies: Competitive Landscape
Table 6.8 GD2 CAR-T Immunotherapies: Clinical Outcomes
Table 6.9 T-Cell Immunotherapies: Clinical Trials
Table 7.1 Key Characteristics of CAR-T Cells
Table 7.2 CAR-T Therapies: Information on Constructs of Clinical Candidates
Table 7.3 Comparison Between First and Second Generation CAR-Ts
Table 7.4 Grading Criteria for Cytokine Release Syndrome
Table 7.5 Safety Switches under Development for CAR-T Therapies
Table 7.6 CD19 CAR-T Immunotherapies: Preclinical Results
Table 7.7 Other Targets under Clinical/Preclinical Studies for CAR-T Therapies
Table 7.8 Kymriah®: Clinical Studies
Table 7.9 Kymriah®: Clinical Trial Endpoints (Acute Lymphoblastic Leukemia)
Table 7.10 Kymriah®: Clinical Trial Endpoints (Chronic Lymphocytic Leukemia/Multiple Myeloma/Non-Hodgkin Lymphoma)
Table 7.11 JCAR Series: Molecules in Clinical Development
Table 7.12 JCAR Series: CAR-T Design
Table 7.13 JCAR014: Current Status of Development
Table 7.14 JCAR017: Current Status of Development
Table 7.15 JCAR018: Current Status of Development
Table 7.16 JCAR020: Current Status of Development
Table 7.17 JCAR023: Current Status of Development
Table 7.18 JCAR024: Current Status of Development
Table 7.19 JCAR Series: Clinical Trial Endpoints (Phase II)
Table 7.20 JCAR Series: Clinical Trial Endpoints (Phase I)
Table 7.21 JCAR Series: Dosage Regimen
Table 7.22 Yescarta®: Clinical Studies
Table 7.23 Yescarta®: Clinical Trial Endpoints
Table 7.24 Yescarta®: Results of ZUMA-1 Phase II (6 months Follow-Up)
Table 7.25 Yescarta®: Results of ZUMA-1 Phase II Results (=3 months Follow-Up)
Table 7.26 Yescarta®: Results of ZUMA-1 Phase I & Phase II Results (3 months Follow-Up)
Table 7.27 CBM CAR-T Series: Clinical Products
Table 7.28 CBM-CD19.1 CAR-T: Clinical Studies
Table 7.29 CBM-CD20 CAR-T: Current Status of Development
Table 7.30 CBM-CD30.1 CAR-T: Current Status of Development
Table 7.31 CBM-EGFR.1 CAR-T: Current Status of Development
Table 7.32 CBM CAR-T Series: Clinical Trial Endpoints
Table 7.33 CBM CAR-T Series: Patent Portfolio
Table 7.34 Takara Bio’s CD19 CAR-T: Current Status of Development
Table 7.35 Takara Bio’s CD19 CAR-T: Clinical Trial Endpoints
Table 7.36 TBI-1501: Dosage Regimen
Table 7.37 AUTO2: Clinical Studies
Table 7.38 AUTO3: Clinical Studies
Table 7.39 Autolus’ Dual Targeting CAR-T Cell Therapies: Clinical Trial Endpoints
Table 7.40 Sinobioway Cell Therapy’s CD19 CAR-T Therapy: Clinical Studies
Table 7.41 Sinobioway Cell Therapy’s EPCAM CAR-T Therapy: Clinical Studies
Table 7.42 Sinobioway Cell Therapy’ Dual Targeting CAR-T Cell Therapies: Clinical Trial Endpoints
Table 7.43 Phase I/II or Phase II CAR-T Therapies of Industry Players
Table 8.1 CAR-T Cell and TCR Based Therapies: Key Differences
Table 8.2 TCR Therapies: Principle Investigators
Table 8.3 NY-ESO TCR: Clinical Studies
Table 8.4 MAGE-A10: Clinical Studies
Table 8.5 MAGE A-4: Current Status of Development
Table 8.6 AFP T-Cell: Current Status of Development
Table 8.7 NY-ESO TCR/MAGE A-10: Clinical Trial Endpoints
Table 8.8 MAGE A-10/MAGE A-4/AFP TCR: Clinical Trial Endpoints
Table 8.9 ALT-801: Clinical Studies
Table 8.10 ALT-801: Clinical Trial Endpoints
Table 8.11 IMCgp100: Clinical Studies
Table 8.12 IMCgp100: Clinical Trial Endpoints
Table 8.13 JTCR016: Clinical Studies
Table 8.14 JTCR016: Clinical Trial Endpoints
Table 8.15 WT1 TCR: Clinical Studies
Table 8.16 WT1 TCR: Clinical Trial Endpoints
Table 8.17 TBI-1301: Clinical Studies
Table 8.18 TBI-1301: Clinical Trial Endpoints
Table 9.1 TIL Therapies: Principle Investigators
Table 9.2 LN-144: Current Status of Development
Table 9.3 LN-144: Clinical Trial Endpoints
Table 9.4 LN-145: Current Status of Development
Table 9.5 LN-145: Clinical Trial Endpoints
Table 9.6 LN-144: Patent Portfolio
Table 9.7 Nantes University Hospital’s TIL Therapy: Clinical Trial Endpoints
Table 9.8 Netherlands Cancer Institute’s TIL Therapy: Clinical Trial Endpoints
Table 10.1 Comparison of Hodgkin’s and Non-Hodgkin’s Lymphoma
Table 10.2 Leukemia: List of Marketed Targeted Therapeutics
Table 10.3 Lymphoma: List of Marketed Targeted Therapeutics
Table 10.4 T-Cell Immunotherapies: Targets under Investigation for Leukemia
Table 10.5 T-Cell Immunotherapies: Targets under Investigation for Lymphoma
Table 10.6 Multiple Myeloma: List of Marketed Targeted Therapeutics
Table 10.7 T-Cell Immunotherapies: Targets under Investigation for Multiple Myeloma
Table 10.8 Melanoma: List of Marketed Targeted Therapeutics
Table 10.9 TIL Therapy: Historical Development of Treatment Protocols for Melanoma at the National Cancer Institute
Table 10.10 Lung Cancer: List of Marketed Targeted Therapeutics
Table 10.11 T-Cell Immunotherapies: Targets under Investigation for Lung Cancer
Table 10.12 Bladder Cancer: List of Marketed Targeted Therapeutics
Table 10.13 Renal Cell Carcinoma: List of Marketed Targeted Therapeutics
Table 10.14 Ovarian Cancer: List of Marketed Targeted Therapeutics
Table 10.15 T-Cell Immunotherapy: Targets under Investigation for Ovarian Cancer
Table 10.16 Breast Cancer: List of Marketed Targeted Therapeutics
Table 10.17 T-Cell Immunotherapies: Targets under Investigation for Breast Cancer
Table 11.1 Editas Medicine: CRISPR/Cas9 Technology, Research Publications
Table 11.2 Editas Medicine: Funding Instances
Table 11.3 Editas Medicine: Collaborations
Table 11.4 Intellia Therapeutics: CRISPR/Cas9 Technology, Research Publications
Table 11.5 Intellia Therapeutics: Funding Instances
Table 11.6 Intellia Therapeutics: Collaborations
Table 11.7 CRISPR Therapeutics: CRIPSR/Cas9 Technology, Research Publications
Table 11.8 CRISPR Therapeutics: Funding Instances
Table 11.9 CRISPR Therapeutics: Collaborations
Table 11.10 Cellectis: Funding Instances
Table 11.11 Cellectis: Collaborations
Table 11.12 bluebird bio: megaTAL Technology, Research Publications
Table 11.13 bluebird bio: Funding Instances
Table 11.14 bluebird bio: Collaborations
Table 11.15 Sangamo BioSciences: Funding Instances
Table 11.16 Sangamo BioSciences: Collaborations
Table 11.17 Unum Therapeutics: Funding Instances
Table 11.18 Unum Therapeutics: NKR-T Platform Related Collaborations
Table 11.19 Celyad: Funding Instances
Table 11.20 Celyad: Collaborations
Table 11.21 Intrexon: Funding Instances
Table 11.22 Intrexon: Collaborations
Table 11.23 Bellicum Pharmaceuticals: Key Switch Technologies
Table 11.24 Bellicum Pharmaceuticals: Switch Technologies, Research Publications
Table 11.25 Bellicum Pharmaceuticals: Funding Instances
Table 11.26 Bellicum Pharmaceuticals: Collaborations
Table 11.27 Theravectys: Funding Instances
Table 11.28 Technologies For CAR-T Safety Enhancement
Table 11.29 Formula Pharmaceuticals: Collaborations
Table 11.30 Celyad: Allogenic Platform Related Collaborations
Table 12.1 T-Cell Immunotherapy Market: Partnerships
Table 13.1 T-Cell Immunotherapy Market: Funding and Investments, Pre-2009-2017
Table 13.2 T-Cell Immunotherapy: Summary of Investments
Table 14.1 List of Other Novel T-Cell Immunotherapies
Table 14.2 Treg Cells: Properties
Table 15.1 Cell Therapy Manufacturing: Companies with In-house Capabilities
Table 15.2 Cell Therapy Manufacturing: Contract Manufacturers
Table 16.1 Price of Marketed Gene/Cell Therapies
Table 16.2 Price of Marketed Targeted Drugs
Table 16.3 T-Cell Immunotherapies: Expert Opinions on Pricing
Table 16.4 CAR-T Therapies: Reimbursement Landscape
Table 17.1 T-Cell Immunotherapies: List of Forecasted Molecules
Table 18.1 Kymriah®: Drug Overview
Table 18.2 Yescarta®: Drug Overview
Table 19.1 Adaptimmune Therapeutics: Company Profile
Table 19.2 Autolus: Company Profile
Table 19.3 bluebird bio: Company Profile
Table 19.4 CARsgen Therapeutics: Company Profile
Table 19.5 Celgene: Company Profile
Table 19.6 Cell Medica: Company Profile
Table 19.7 Cellectis: Company Profile
Table 19.8 Cellular Biomedicine Group: Company Profile
Table 19.9 Immunocore: Company Profile
Table 19.10 Innovative Cellular Therapeutics: Company Profile
Table 19.11 Iovance Biotherapeutics: Company Profile
Table 19.12 Kite Pharma: Company Profile
Table 19.13 Lion TCR: Company Profile
Table 19.14 Novartis: Company Profile
Table 19.15 Sinobioway Cell Therapy: Company Profile
Table 19.16 Takara Bio: Company Profile
Table 19.17 Unum Therapeutics: Company Profile
Table 19.18 ZIOPHARM Oncology: Company Profile
Table 21.1 Cell Therapies: Key Highlights
Table 21.2 Celyad: Key Highlights
Table 21.3 Changhai Hospital: Key Highlights
Table 21.4 Iovance Biotherapeutics: Key Highlights
Table 21.5 Kite Pharma: Key Highlights
Table 21.6 Lion TCR: Key Highlights
Table 21.7 Theravectys: Key Highlights
Table 21.8 TxCell: Key Highlights
Table 21.9 University of Colorado: Key Highlights
Table 21.10 Waisman Biomanufacturing: Key Highlights
Table 22.1 T-Cell Immunotherapy Pipeline: Distribution by Type of Product
Table 22.2 T-Cell Immunotherapy Pipeline: Distribution by Type of Developer
Table 22.3 T-Cell Immunotherapy Pipeline: Distribution by Type of Developer and Type of Product
Table 22.4 T-Cell Immunotherapy Pipeline: Distribution by Phase of Development
Table 22.5 T-Cell Immunotherapy Pipeline: Distribution by Phase of Development and Type of Product
Table 22.6 T-Cell Immunotherapy Pipeline: Distribution by Target Therapeutic Areas
Table 22.7 T-Cell Immunotherapy Pipeline: Distribution by Target Therapeutic Areas and Type of Product
Table 22.8 T-Cell Immunotherapy Pipeline: Popular Target Indications
Table 22.9 CAR-T Immunotherapy Pipeline: Popular Target Indications
Table 22.10 TCR Immunotherapy Pipeline: Popular Target Indications
Table 22.11 TIL Immunotherapy Pipeline: Popular Target Indications
Table 22.12 CAR-T Cell Immunotherapy Pipeline: Distribution by Target Antigen
Table 22.13 TCR Cell Immunotherapy Pipeline: Distribution by Target Antigen
Table 22.14 T-Cell Immunotherapy Pipeline: Distribution by Source of T-Cells
Table 22.15 T-Cell Immunotherapy Pipeline: Distribution by Source of T-Cells and Type of Product
Table 22.16 T-Cell Immunotherapy Developer Landscape: Distribution by Source of T-Cells and Type of Product
Table 22.17 T-Cell Immunotherapy Pipeline: Distribution by Route of Administration
Table 22.18 T-Cell Immunotherapy Pipeline: Distribution by Route of Administration and Type of Product
Table 22.19 T-Cell Immunotherapy Clinical Pipeline: Active Industry Players
Table 22.20 T-Cell Immunotherapy Preclinical Pipeline: Active Industry Players
Table 22.21 T-Cell Immunotherapy Clinical Pipeline: Active Non-Industry Players
Table 22.22 T-Cell Immunotherapy Preclinical Pipeline: Active Non-Industry Players
Table 22.23 T-Cell Immunotherapies: Popular Targets in Hematological Cancer
Table 22.24 T-Cell Immunotherapies: Popular Targets in Solid Tumor
Table 22.25 CAR-T Clinical Trials: Cumulative Trend (Pre-2012-2018)
Table 22.26 CAR-T Clinical Trials: Geographical Landscape (Pre-2016 and 2018)
Table 22.27 T-Cell Immunotherapies, Clinical Trials: Distribution by Type of Product
Table 22.28 T-Cell Immunotherapies, Clinical Trials: Distribution by Phase of Development
Table 22.29 T-Cell Immunotherapies, Clinical Trials: Distribution by Phase of Development and Type of Product
Table 22.30 T-Cell Immunotherapies, Clinical Trials: Distribution by Patient Segment
Table 22.31 T-Cell Immunotherapies, Clinical Trials: Distribution by Patient Segment and Type of Product
Table 22.32 T-Cell Immunotherapies, Clinical Trials: Distribution by Type of Therapy
Table 22.33 T-Cell Immunotherapies, Clinical Trials: Distribution by Type of Therapy and Type of Product
Table 22.34 CAR-Constructs: Distribution by Generation of CAR-T Therapies
Table 22.35 CAR-Constructs: Distribution by Type of scFv used
Table 22.36 CAR-Constructs: Distribution by Type of Vector
Table 22.37 CAR-Constructs: Distribution by Type of Co-Stimulatory Domain(s)
Table 22.38 T-Cell Immunotherapy Partnerships: Cumulative Trend, Pre-2011-2018
Table 22.39 T-Cell Immunotherapy Partnerships: Distribution by Type of Partnership Model, Pre-2018-2018
Table 22.40 T-Cell Immunotherapy Partnerships: Most Active Players
Table 22.41 T-Cell Immunotherapy Partnerships: Most Active Non-Industry Players
Table 22.44 T-Cell Immunotherapy Partnerships: Distribution by Type of Therapy
Table 22.45 T-Cell Immunotherapy Partnerships: Distribution by Product Therapy
Table 22.46 T-Cell Immunotherapy Funding Instances: Cumulative Number of Investments by Year, Pre-2009-2017
Table 22.47 T-Cell Immunotherapy Funding Instances: Cumulative Amount Invested by Year, Pre-2009-2017 (USD Million)
Table 22.48 T-Cell Immunotherapies Funding Instances: Distribution by Type of Funding
Table 22.49 T-Cell Immunotherapies Funding Instances: Distribution by Total Amount Invested by Type of Funding (USD Million)
Table 22.50 T-Cell Immunotherapies: Analysis of Most Active Industry Players by Number of Funding Instances
Table 22.51 Other T-Cell Immunotherapies: Distribution by Phase of Development
Table 22.52 Other T-Cell Immunotherapies: Distribution by Target Therapeutic Areas
Table 22.53 Other T-Cell Immunotherapies: Distribution by Type of Cells
Table 22.54 Other T-Cell Immunotherapies: Distribution by Source of T-Cells
Table 22.55 Overall T-Cell Immunotherapy Market, 2018-2030: Conservative Scenario (USD Billion)
Table 22.56 Overall T-Cell Immunotherapy Market, 2018-2030: Base Scenario (USD Billion)
Table 22.57 Overall T-Cell Immunotherapy Market, 2018-2030: Opportunistic Scenario (USD Billion)
Table 22.58 T-Cell Immunotherapy Market: Distribution by Type of Product, 2018, 2025 and 2030 (USD Billion)
Table 22.59 T-Cell Immunotherapy Market: Distribution by Geography, 2018, 2025 and 2030 (USD Billion)
Table 22.60 T-Cell Immunotherapy Market: Distribution by Target Indication, 2018, 2025 and 2030 (USD Billion)
Table 22.61 Overall CAR-T Therapy Market, 2018-2030: Conservative Scenario (USD Billion)
Table 22.62 Overall CAR-T Therapy Market, 2018-2030: Base Scenario (USD Billion)
Table 22.63 Overall CAR-T Therapy Market, 2018-2030: Opportunistic Scenario (USD Billion)
Table 22.64 Kymriah® (Novartis) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 22.65 Kymriah® (Novartis) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 22.66 Kymriah® (Novartis) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
Table 22.67 Yescarta® (Gilead Sciences) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 22.68 Yescarta® (Gilead Sciences) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 22.69 Yescarta® (Gilead Sciences) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
Table 22.70 CD19 CAR-T (Sinobioway Cell Therapy/The First Affiliated Hospital of Anhui Medical University) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 22.71 CD19 CAR-T (Sinobioway Cell Therapy/The First Affiliated Hospital of Anhui Medical University) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 22.72 CD19 CAR-T (Sinobioway Cell Therapy/The First Affiliated Hospital of Anhui Medical University) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
Table 22.73 GPC3 CAR-T (Shanghai GeneChem) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 22.74 GPC3 CAR-T (Shanghai GeneChem) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 22.75 GPC3 CAR-T (Shanghai GeneChem) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
Table 22.76 TBI-1501 (Takara Bio/Jichi Medical University) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 22.77 TBI-1501 (Takara Bio/Jichi Medical University) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 22.78 TBI-1501 (Takara Bio/Jichi Medical University) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
Table 22.79 JCAR017 (Juno Therapeutics/Celgene) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 22.80 JCAR017 (Juno Therapeutics/Celgene) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 22.81 JCAR017 (Juno Therapeutics/Celgene) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
Table 22.82 MB-CART19.1 (Miltenyi Biotec/Shanghai Children's Medical Center) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 22.83 MB-CART19.1 (Miltenyi Biotec/Shanghai Children's Medical Center) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 22.84 MB-CART19.1 (Miltenyi Biotec/Shanghai Children's Medical Center) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
Table 22.85 IM19 CAR-T (Beijing Immunochina Medical Science and Technology) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 22.86 IM19 CAR-T (Beijing Immunochina Medical Science and Technology) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 22.87 IM19 CAR-T (Beijing Immunochina Medical Science and Technology) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
Table 22.88 PCAR-019 (PersonGen BioTherapeutics) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 22.89 PCAR-019 (PersonGen BioTherapeutics) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 22.90 PCAR-019 (PersonGen BioTherapeutics) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
Table 22.91 AUTO2 (Autolus) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 22.92 AUTO2 (Autolus) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 22.93 AUTO2 (Autolus) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
Table 22.94 AUTO3 (Autolus) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 22.95 AUTO3 (Autolus) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 22.96 AUTO3 (Autolus) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
Table 22.97 BCMA CAR-T (The Beijing Pregene Science and Technology/Henan Cancer Hospital) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 22.98 BCMA CAR-T (The Beijing Pregene Science and Technology/Henan Cancer Hospital) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 22.99 BCMA CAR-T (The Beijing Pregene Science and Technology/Henan Cancer Hospital) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
Table 22.100 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology Company/Henan Cancer Hospital) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 22.101 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology Company/Henan Cancer Hospital) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 22.102 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology Company/Henan Cancer Hospital) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
Table 22.103 CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology/The First Affiliated Hospital of Soochow University) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 22.104 CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology/The First Affiliated Hospital of Soochow University) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 22.105 CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology/The First Affiliated Hospital of Soochow University) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
Table 22.106 LCAR-B38M CAR-T (Nanjing Legend Biotech) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 22.107 LCAR-B38M CAR-T (Nanjing Legend Biotech) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 22.108 LCAR-B38M CAR-T (Nanjing Legend Biotech) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
Table 22.109 CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 22.110 CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 22.111 CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
Table 22.112 bb2121 (Celgene/bluebird bio) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 22.113 bb2121 (Celgene/bluebird bio) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 22.114 bb2121 (Celgene/bluebird bio) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
Table 22.115 IMCgp100 (Immunocore) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 22.116 IMCgp100 (Immunocore) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 22.117 IMCgp100 (Immunocore) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
Table 22.118 NY-ESO-1 TCR (Adaptimmune/GSK) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 22.119 NY-ESO-1 TCR (Adaptimmune/GSK) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 22.120 NY-ESO-1 TCR (Adaptimmune/GSK) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
Table 22.121 JTCR016 (Juno Therapeutics) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 22.122 JTCR016 (Juno Therapeutics) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 22.123 JTCR016 (Juno Therapeutics) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
Table 22.124 LTCR-H1-2 (Lion TCR/Agency for Science, Technology and Research/Third Affiliated Hospital/Sun Yat-Sen University) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 22.125 LTCR-H1-2 (Lion TCR/Agency for Science, Technology and Research/Third Affiliated Hospital/Sun Yat-Sen University) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 22.126 LTCR-H1-2 (Lion TCR/Agency for Science, Technology and Research/Third Affiliated Hospital/Sun Yat-Sen University) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
Table 22.127 ALT 801 (Altor Bioscience) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 22.128 ALT 801 (Altor Bioscience) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 22.129 ALT 801 (Altor Bioscience) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
Table 22.130 TBI-1301 (Takara Bio) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 22.131 TBI-1301 (Takara Bio) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 22.132 TBI-1301 (Takara Bio) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
Table 22.133 TIL (Nantes University Hospital) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 22.134 TIL (Nantes University Hospital) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 22.135 TIL (Nantes University Hospital) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
Table 22.136 TIL (Netherlands Cancer Institute) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 22.137 TIL (Netherlands Cancer Institute) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 22.138 TIL (Netherlands Cancer Institute) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
Table 22.139 LN-144 (Iovance Biotherapeutics) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 22.140 LN-144 (Iovance Biotherapeutics) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 22.141 LN-144 (Iovance Biotherapeutics) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)
Table 22.142 LN-145 (Iovance Biotherapeutics) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 22.143 LN-145 (Iovance Biotherapeutics) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 22.144 LN-145 (Iovance Biotherapeutics) Sales Forecast (Till 2030): Opportunistic Scenario (USD Million)

LIST OF FIGURES
Figure 3.1 The Four Pillars of Cancer Therapy
Figure 3.2 Difference between Active and Passive Immunotherapies
Figure 3.3 Difference between Specific and Non-Specific Immunotherapies
Figure 3.4 3Es of the Immune System
Figure 3.5 Strategies Employed for the Redirection of T-Cells
Figure 3.6 T-Cell Manufacturing: General Procedure
Figure 3.7 T-Cell Immunotherapies: Targeted Therapeutic Areas
Figure 3.8 T-Cell Immunotherapies: Key Challenges
Figure 4.1 T-Cell Immunotherapy Social Media Analysis: Twitter Trends, 2012-2017
Figure 4.2 T-Cell Immunotherapy Social Media Analysis: Popular Keywords on Twitter, 2012-2017
Figure 4.3 T-Cell Immunotherapy Social Media Analysis: Twitter, Most Popular Candidates, 2012-2017
Figure 5.1 T-Cell Immunotherapy Pipeline: Distribution by Type of Product
Figure 5.2 T-Cell Immunotherapy Pipeline: Distribution by Type of Developer
Figure 5.3 T-Cell Immunotherapy Pipeline: Distribution by Type of Developer and Type of Product
Figure 5.4 T-Cell Immunotherapy Pipeline: Distribution by Phase of Development
Figure 5.5 T-Cell Immunotherapy Pipeline: Distribution by Phase of Development and Type of Product
Figure 5.6 T-Cell Immunotherapy Pipeline: Distribution by Target Therapeutic Area
Figure 5.7 T-Cell Immunotherapy Pipeline: Distribution by Target Therapeutic Area and Type of Product
Figure 5.8 T-Cell Immunotherapy Pipeline: Popular Target Indications
Figure 5.9 CAR-T Immunotherapy Pipeline: Popular Target Indications
Figure 5.10 TCR Immunotherapy Pipeline: Popular Target Indications
Figure 5.11 TIL Immunotherapy Pipeline: Popular Target Indications
Figure 5.12 CAR-T Immunotherapy Pipeline: Distribution by Target Antigen
Figure 5.13 TCR Immunotherapy Pipeline: Distribution by Target Antigen
Figure 5.14 T-Cell Immunotherapy Pipeline: Distribution by Source of T-Cells
Figure 5.15 T-Cell Immunotherapy Pipeline: Distribution by Source of T-Cells and Type of Product
Figure 5.16 T-Cell Immunotherapy Developer Landscape: Distribution by Source of T-Cells and Type of Product
Figure 5.17 T-Cell Immunotherapy Pipeline: Distribution by Route of Administration
Figure 5.18 T-Cell Immunotherapy Pipeline: and Type of Product
Figure 5.19 T-Cell Immunotherapy Pipeline: Active Industry Players in Clinical Development
Figure 5.20 T-Cell Immunotherapy Pipeline: Active Industry Players in Preclinical Development
Figure 5.21 T-Cell Immunotherapy Pipeline: Active Non-Industry Players in Clinical Development
Figure 5.22 T-Cell Immunotherapy Pipeline: Active Non-Industry Players in Preclinical Development
Figure 6.1 T-Cell Immunotherapies: Popular Targets in Hematological Cancer
Figure 6.2 T-Cell Immunotherapies: Popular Targets in Solid Tumor
Figure 6.3 CAR-T Clinical Trials: Cumulative Trend (Pre-2012-2018)
Figure 6.4 CAR-T Clinical Trials: Geographic Landscape (Pre-2016 and 2018)
Figure 6.5 T-Cell Immunotherapies: Distribution of Clinical Trials by Type of Product
Figure 6.6 T-Cell Immunotherapies: Distribution of Clinical Trials by Phase of Development
Figure 6.7 T-Cell Immunotherapies: Distribution of Clinical Trial by Phase of Development Across CAR-T, TCR and TIL
Figure 6.8 T-Cell Immunotherapies: Distribution of Clinical Trials by Patient Segment
Figure 6.9 T-Cell Immunotherapies: Distribution of Clinical Trial by Patient Segment and Type of Product
Figure 6.10 T-Cell Immunotherapies: Distribution of Clinical Trials by Type of Therapy
Figure 6.11 T-Cell Immunotherapies: Distribution of Clinical Trial by Type of Therapy and Type of Product
Figure 7.1 Historical Timeline: Development of CAR-T cells
Figure 7.2 CAR-T Cell Therapy: Geographical Distribution of Key Opinion Leaders
Figure 7.3 CAR-T Therapy: Prominent Key Opinion Leaders
Figure 7.4 CAR-T: Structure and Domains
Figure 7.5 CAR-Construction: Distribution by Generation of CAR-T Therapies
Figure 7.6 CAR-Construction: Distribution by Type scFv Used in CAR-T Therapies
Figure 7.7 CAR-Construction: Distribution by Type of Vector
Figure 7.8 CAR-Construction: Distribution by Type of Co-Stimulatory Domain(s)
Figure 7.9 CAR-T: CAR Generations Layout
Figure 7.10 Development of CAR-T Cells
Figure 7.11 Challenges Associated with CAR-T Therapy
Figure 7.12 Kymriah: Industry Sponsored Clinical Trial Design
Figure 7.13 Kymriah: Non-Industry Sponsored Clinical Trial Design
Figure 7.14 JCAR Series: Industry Sponsored Clinical Trial Design
Figure 7.15 JCAR Series: Non-Industry Sponsored Clinical Trial Design
Figure 7.16 Yescarta: Clinical Trial Design
Figure 7.17 Manufacturing of CD19 CAR-T Cells: Process Comparison
Figure 7.18 Cellular Biomedicine’s CAR-T Series: Clinical Trial Design
Figure 7.19 Takara Bio’s CD19 CAR-T: Clinical Trial Design
Figure 7.20 Autolus’s Dual Targeting CAR-T Cell Therapies: Clinical Trial Design
Figure 7.21 Sinobioway Cell Therapy’s Dual Targeting CAR-T Cell Therapies: Clinical Trial Design
Figure 8.1 TCR Cell Therapy: Geographical Distribution of Key Opinion Leaders
Figure 8.2 TCR Therapy: Prominent Key Opinion Leaders
Figure 8.3 TCR Cell Therapy: Development Process
Figure 8.4 NY-ESO TCR: Industry Sponsored Clinical Trial Design
Figure 8.5 MAGE A-10 TCR: Industry Sponsored Clinical Trial Design
Figure 8.6 MAGE A-4 TCR: Industry Sponsored Clinical Trial Design
Figure 8.7 AFP TCR: Industry Sponsored Clinical Trial Design
Figure 8.8 ALT-801: Clinical Trial Design
Figure 8.9 IMCgp100: Clinical Trial Design
Figure 8.10 JTCR016: Clinical Trial Design
Figure 8.11 WT1 TCR: Clinical Trial Design
Figure 8.12 TBI-1301: Clinical Trial Design
Figure 9.1 TIL Cell Therapy: Geographical Distribution of Key Opinion Leaders
Figure 9.2 TIL Therapy: Prominent Key Opinion Leaders
Figure 9.3 TIL Cell Therapy: Manufacturing Process
Figure 9.4 LN-144: Clinical Trial Design
Figure 9.5 LN-145: Clinical Trial Design
Figure 9.6 Nantes University Hospital’s TIL Therapy: Clinical Trial Design
Figure 9.7 Nantes University Hospital’s TIL Therapy: Production Procedure
Figure 9.8 Netherlands Cancer Institute’s TIL Therapy: Clinical Trial Design
Figure 10.1 Leukemia: Classification
Figure 10.2 Leukemia: Global Epidemiological Distribution
Figure 10.3 Lymphoma: Global Epidemiological Distribution
Figure 10.4 Multiple Myeloma: Global Epidemiological Distribution
Figure 10.5 Melanoma: Global Epidemiological Distribution
Figure 10.6 Lung Cancers: Classification
Figure 10.7 Lung Cancer: Global Epidemiological Distribution
Figure 10.8 Bladder Cancer: Global Epidemiological Distribution
Figure 10.9 Kidney Cancer: Global Epidemiological Distribution
Figure 10.10 Ovarian Cancer: Global Epidemiological Distribution
Figure 10.11 Breast Cancer: Global Epidemiological Distribution
Figure 11.1 Genome Editing Technologies: Applications
Figure 11.2 Genome Editing: Emerging Technology Platforms Used in T-Cell Platforms
Figure 11.3 T-Cell Therapy: Key Technologies to Enhance Features/Characteristics
Figure 11.4 Properties of Enhanced T-Cell Platform
Figure 11.5 Cellectis: Allogenic CAR-T Platform, Comparison with Autologous CAR-T Platform
Figure 12.1 T-Cell Immunotherapy Partnerships: Cumulative Trend (Pre-2011-2018)
Figure 12.2 T-Cell Immunotherapy Partnerships: Distribution by Type of Partnership Model, Pre-2011-2018
Figure 12.3 T-Cell Immunotherapy Partnerships: Most Active Players, Pre-2011 to 2018
Figure 12.4 T-Cell Immunotherapy Partnerships: Most Active Non-Industry Players, Pre- 2011-2018
Figure 12.5 T-Cell Immunotherapy Partnerships: Distribution by Type of Therapy, Pre- 2011-2018
Figure 12.6 T-Cell Immunotherapy Partnerships: Distribution by Product Therapy, Pre- 2011-2018
Figure 13.1 T-Cell Immunotherapies: Funding Instances, Cumulative Number of Investments by Year, Pre-2009-2017
Figure 13.2 T-Cell Immunotherapies: Funding Instances, Cumulative Distribution of Amount Invested by Year, Pre-2009-2017 (USD Million)
Figure 13.3 T-Cell Immunotherapies: Distribution by Type of Funding, Pre-2009-2017
Figure 13.4 T-Cell Immunotherapies: Total Amount Invested by Type of Funding, Pre-2009-2017 (USD Million)
Figure 13.5 T-Cell Immunotherapy: Most Active Players
Figure 14.1 Other T-Cell Immunotherapies: Distribution by Phase of Development
Figure 14.2 Other T-Cell Immunotherapies: Distribution by Target Therapeutic Area
Figure 14.3 Other T-Cell Immunotherapies: Distribution by Type of Cells
Figure 14.4 Other T-Cell Immunotherapies: Distribution by Source of T-Cells
Figure 14.5 Treg Cells: Functions
Figure 15.1 Cell Therapy Manufacturing: Key Steps
Figure 15.2 Cell Therapy Manufacturing: Scenarios
Figure 15.3 T-Cell Immunotherapy Manufacturing: Key Collaborations
Figure 16.1 Targeted Therapies: Pricing Model Based on Patient Segment
Figure 17.1 Overall T-Cell Immunotherapy Market, 2016-2026: Base Scenario (USD Billion)
Figure 17.2 T-Cell Immunotherapy Market: Distribution by Type of Therapy, 2018, 2025 and 2030 (USD Billion)
Figure 17.3 T-Cell Immunotherapy Market: Distribution by Geography, 2018, 2025 and 2030 (USD Billion)
Figure 17.4 T-Cell Immunotherapy Market: Distribution by Target Indication, 2018, 2025 and 2030 (USD Billion)
Figure 17.5 Overall CAR-T Therapy Market Forecast, 2018-2030: Base Scenario (USD Billion)
Figure 17.6 Kymriah (Novartis): Current Status of Development
Figure 17.7 Kymriah (Novartis) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 17.8 Yescarta (Gilead Sciences): Current Status of Development
Figure 17.9 Yescarta (Gilead Sciences) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 17.10 CD19 CAR-T (Sinobioway Cell Therapy/The First Affiliated Hospital of Anhui Medical University): Current Status of Development
Figure 17.11 CD19 CAR-T (Sinobioway Cell Therapy/The First Affiliated Hospital of Anhui Medical University) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 17.12 GPC3 CAR-T (Shanghai GeneChem): Current Status of Development
Figure 17.13 GPC3 CAR-T (Shanghai GeneChem) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 17.14 TBI-1501 (Takara Bio/Jichi Medical University): Current Status of Development
Figure 17.15 TBI-1501 (Takara Bio/Jichi Medical University) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 17.16 JCAR017 (Juno Therapeutics/Celgene): Current Status of Development
Figure 17.17 JCAR017 (Juno Therapeutics/Celgene) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 17.18 MB-CART19.1 (Miltenyi Biotec/Shanghai Children's Medical Center): Current Status of Development
Figure 17.19 MB-CART19.1 (Miltenyi Biotec/Shanghai Children's Medical Center) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 17.20 IM19 CAR-T (Beijing Immunochina Medical Science & Technology): Current Status of Development
Figure 17.21 IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 17.22 PCAR-019 (PersonGen BioTherapeutics): Current Status of Development
Figure 17.23 PCAR-019 (PersonGen BioTherapeutics) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 17.24 AUTO2 (Autolus): Current Status of Development
Figure 17.25 AUTO2 (Autolus) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 17.26 AUTO3 (Autolus): Current Status of Development
Figure 17.27 AUTO3 (Autolus) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 17.28 BCMA CAR-T (The Beijing Pregene Science and Technology/Henan Cancer Hospital): Current Status of Development
Figure 17.29 BCMA CAR-T (The Beijing Pregene Science and Technology/Henan Cancer Hospital) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 17.30 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology Company/Henan Cancer Hospital): Current Status of Development
Figure 17.31 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology Company/Henan Cancer Hospital) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 17.32 CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology/The First Affiliated Hospital of Soochow University): Current Status of Development
Figure 17.33 CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology/The First Affiliated Hospital of Soochow University) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 17.34 LCAR-B38M CAR-T (Nanjing Legend Biotech): Current of Development
Figure 17.35 LCAR-B38M CAR-T (Nanjing Legend Biotech) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 17.36 CD19 CAR-T (Shanghai Bioray Laboratory): Current Status of Development
Figure 17.37 CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 17.38 bb2121 (Celgene/bluebird bio): Current Status of Development
Figure 17.39 bb2121 (Celgene/bluebird bio) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 17.40 IMCgp100 (Immunocore): Current Status of Development
Figure 17.41 IMCgp100 (Immunocore) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 17.42 NY-ESO-1 TCR (Adaptimmune/GSK): Current Status of Development
Figure 17.43 NY-ESO-1 TCR (Adaptimmune/GSK) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 17.44 JTCR016 (Juno Therapeutics): Current Status of Development
Figure 17.45 JTCR016 (Juno Therapeutics) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 17.46 LTCR-H1-2 (Lion TCR/Agency for Science, Technology and Research/Third Affiliated Hospital/Sun Yat-Sen University): Current Status of Development
Figure 17.47 LTCR-H1-2 (Lion TCR/Agency for Science, Technology and Research/Third Affiliated Hospital/Sun Yat-Sen University) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 17.48 ALT 801 (Altor Bioscience): Current Status of Development
Figure 17.49 ALT 801 (Altor Bioscience) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 17.50 TBI-1301 (Takara Bio): Current Status of Development
Figure 17.51 TBI-1301 (Takara Bio) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 17.52 TIL (Nantes University Hospital): Current Status of Development
Figure 17.53 TIL (Nantes University Hospital) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 17.54 TIL (The Netherland Cancer Institute): Current Status of Development
Figure 17.55 TIL (The Netherland Cancer Institute) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 17.56 LN-144 (Iovance Biotherapeutics): Current Status of Development
Figure 17.57 LN-144 (Iovance Biotherapeutics) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 17.58 LN-145 (Iovance Biotherapeutics): Current Status of Development
Figure 17.59 LN-145 (Iovance Biotherapeutics) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 18.1 Promotional/Marketing Strategy: Product Website Analysis
Figure 18.2 Promotional/Marketing Strategy: Patient Support Services and Informative Downloads
Figure 18.3 Product Website Analysis: Kymriah, Messages for Healthcare Professionals
Figure 18.4 Product Website Analysis: Kymriah, Messages for Patients
Figure 18.5 Product Website Analysis: Kymriah, Patient Support Program
Figure 18.6 Kymriah, Presence in Conferences
Figure 18.7 Product Website Analysis: Yescarta, Messages for Patients and Caregivers
Figure 18.8 Product Website Analysis: Kymriah, Kite Konnect
Figure 18.9 Product Website Analysis: Yescarta, Platform for Products Complaints, Reporting Adverse Events and Requesting Medical Information
Figure 18.10 Yescarta, Presence in Conferences
Figure 20.1 T-Cell Immunotherapy Market Landscape: Industry Participants
Figure 20.2 T-Cell Immunotherapy Market Landscape: Non-Industry Participants
Figure 20.3 T-Cell Immunotherapy Market Forecast, 2018, 2025, 2030: Conservative, Base and Optimistic Scenarios (USD Billion)

Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Abramson Cancer Center
  • Broadfin Capital
  • Flagship Pioneering
  • Lifeline Ventures
  • PolyBioCept
  • Target ALS Foundation
  • MORE

Research Methodology

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts’ views

While the focus has been on forecasting the market over the coming 12 years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

  • Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the T-cell immunotherapy market in the short to mid-term and long term.
  • Chapter 3 provides a general overview of T-cell immunotherapies. In this section, we have briefly discussed the conventional forms of therapy that are being used for the treatment of various oncological indications. Further, it includes a discussion on the advent and historical evolution of cancer immunotherapy, general manufacturing procedure of T-cell immunotherapies, factors supporting the growing popularity of T-cell based therapies and the challenges associated with such therapies.
  • Chapter 4 provides insights on the popularity of T-cell immunotherapies on the social media platform, Twitter. The section highlights the yearly distribution of tweets posted on the platform in the time period 2012-2017, and the most significant events responsible for increase in the volume of tweets each year. Additionally, the chapter showcases the most frequently mentioned keywords and drug candidates, as observed on social media.
  • Chapter 5 provides information on around 500 T-cell immunotherapies that are currently in different stages of development (clinical and preclinical/discovery). It features a comprehensive analysis of pipeline molecules with respect to the type of therapy (CAR-T, TCR and TIL), type of developer(s), phase of development, target therapeutic areas and indications, key target antigens, source of T-cells (autologous and allogenic) and route of administration. Further, the chapter identifies the most active players (in terms of number of pipeline candidates) and features a logo landscape representation, highlighting product developers in North America, Europe and the Asia Pacific region.
  • Chapter 6 presents a collection of key insights derived from the study. It includes a bubble analysis, highlighting the most popular targets of CAR-T and TCR therapies in hematological cancer and solid tumor space. Further, the chapter includes an analysis on global CAR-T trials registered between 2009 to 2018, featuring the year wise trend and distribution of CAR-T trials across different geographies. In addition, it includes comprehensive analysis of more than 400 clinical trials that have been completed or are currently being conducted to evaluate T-cell immunotherapies with respect to the type of T-cell immunotherapy (CAR-T, TCR and TIL), phase of development, patient segment, and type of therapy (monotherapy and combination therapy).
  • Chapter 7 focuses on CAR-T cell based therapies and highlights the prevailing trends pertaining to ongoing research in this field. It features a discussion on the molecular targets that are currently under investigation and the current challenges (such as toxicity issues) that are associated with this segment. To offer due credit to the work of eminent researchers in this domain, we have mapped the presence of key opinion leaders (who are involved in this field of research) across the globe. In addition, we have presented an analysis of the CAR constructs being used in the clinical CAR-T therapies on the basis of generation of CAR-T therapy, type of binding domain, type of vector and type of co-stimulatory domain. This section also includes detailed profiles of the approved/late stage CAR-T cell therapies. Each profile features a general overview of the therapy and provides information on its history of development, clinical trial timeline, clinical trial results, information on manufacturing, estimated cost of treatment and treatment regimen details.
  • Chapter 8 focuses on TCR cell based therapies and highlights the prevailing trends pertaining to the ongoing research in this field. It features a discussion on the molecular targets that are currently under investigation and the current challenges (such as toxicity issues) that are associated with this segment. To offer due credit to the work of eminent researchers in this domain, we have mapped the presence of key opinion leaders (who are involved in this field of research) across the globe. This section also includes detailed profiles of the late stage TCR therapies. Each profile features a general overview of the therapy and provides information on its history of development, clinical trial timeline, clinical trial results, information on manufacturing, estimated cost of treatment and treatment regimen details.
  • Chapter 9 elaborates on the TIL based therapies and highlights the prevailing trends pertaining to the ongoing research in this field. To offer due credit to the work of eminent researchers in this domain, we have mapped the presence of key opinion leaders (who are involved in this field of research) across the globe. This section also includes detailed profiles of the late stage TIL therapies. Each profile features a general overview of the therapy and provides information on its history of development, clinical trial timeline, clinical trial results, information on manufacturing, estimated cost of treatment and treatment regimen details.
  • Chapter 10 identifies the most commonly targeted therapeutic indications, including hematological cancers and solid tumors and features brief discussions on the T-cell therapies being developed against them. The section also highlights key epidemiological facts and the currently available treatment options for each indication.
  • Chapter 11 provides a list of technology platforms that are either available in the market or under designed for the development of T-cell immunotherapies. It features brief profiles of some of the key technologies as well. Each profile contains details on the various pipeline molecules that have been/are being developed using the technology, its advantages and the associated partnerships.
  • Chapter 12 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst players in this market in the past few years. Further, the partnership activity in this domain has been analyzed on the basis of the type of partnership model (R&D collaborations, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements and others, the companies involved, the type of therapy and prominent product candidates involved.
  • Chapter 13 provides details on the various investments and grants that have been awarded to players focused on the development of T-cell immunotherapies. It includes a detailed analysis of the funding instances that have taken place in the period between 2000 to 2017, highlighting the growing interest of venture capital (VC) community and other strategic investors in this domain.
  • Chapter 14 features details of other T-cell based therapies, apart from CAR-Ts, TCRs and TILs, which are currently being investigated. It presents a detailed analysis of the approved/clinical products in this domain, including information on the current phase of development, target therapeutic areas, type of cells, and source of T-cells. Additionally, we have provided a brief overview of the upcoming therapies, along with details on their mechanisms of action.
  • Chapter 15 provides insights on cell therapy manufacturing, highlighting the current challenges that exist in this domain, and the pre-requisites for owning and maintaining cell therapy manufacturing sites. It includes a list of various cell therapy manufacturers, covering both contract manufacturing organizations and companies with in-house manufacturing capabilities. For the players mentioned in the chapter, we have included details on location of various manufacturing facilities, the products being manufactured, scale of operation and compliance to cGMP standards.
  • Chapter 16 highlights our views on the various factors that must be taken into consideration while deciding the prices of cell-based therapies. It features discussions on different models/approaches that a pharmaceutical company may choose to follow to decide the price at which their T-cell based immunotherapy product can be marketed. Additionally, we have provided a brief overview of the reimbursement consideration for T-cell immunotherapies and a case study on the National Institute for Health and Care Excellence (NICE) appraisal of CAR-T therapy.
  • Chapter 17 features an elaborate discussion on the future commercial opportunity offered by T-cell therapies. It provides a comprehensive market forecast analysis for molecules that are approved or are in phase I/II, phase II and phase III of development, taking into consideration the target patient population, existing/future competition, likely adoption rates and the likely price of different therapies. The chapter also presents a detailed market segmentation on the basis of type of therapy (CAR-T, TCR and TIL), geography (North America, Europe and Asia Pacific) and target indications (acute lymphoblastic leukemia, acute myeloid leukemia, bladder cancer, cervical carcinoma, chronic lymphocytic leukemia, esophageal cancer, head and neck cancer, multiple myeloma, hepatocellular carcinoma, melanoma, non-Hodgkin’s lymphoma, non-small cell lung cancer, ovarian cancer and synovial sarcoma).
  • Chapter 18 highlights the key promotional strategies that are being implemented by the developers of the marketed products, Kymriah and Yescarta. The promotional aspects covered in the chapter include details that are provided on the product website (covering key messages for patients and healthcare professionals), patient support offerings and informative downloadable content.
  • Chapter 19 includes brief company profiles of the leading players in the T-cell immunotherapy market. Each company profile includes an overview of the developer and brief description of the product portfolio specific to CAR-T, TCR and TIL therapies, technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic/venture capital investments made in these companies.
  • Chapter 20 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.
  • Chapter 21 is a collection of transcripts of interviews conducted with key stakeholders in the market. In this chapter, we have presented the details of our conversations with Adrian Bot (Vice President, Scientific Affairs, Kite Pharma), Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys), Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing), Enkhtsetseg Purev (Assistant Professor Of Medicine, University Of Colorado), Miguel Forte (Chief Operating Officer, TxCell), Peter Ho (Director, Process Development, Iovance Biotherapeutics), Tim Oldham (Chief Executive Officer, Cell Therapies), Victor Lietao Li (Co-Founder & Chief Executive Officer, Lion TCR), Vincent Brichard (Vice President, Immuno-Oncology, Celyad) and Xian-Bao Zhan (Professor Of Medicine and Director, Department Of Oncology, Changhai Hospital).
  • Chapter 22 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
  • Chapter 23 is an appendix, which contains the list of companies and organizations mentioned in the report.
Note: Product cover images may vary from those shown
5 of 6
  • A*STAR’s Genome Institute of Singapore
  • Abramson Cancer Center
  • AbVitro
  • Acerta Pharma
  • Acer Therapeutics
  • Adaptimmune Therapeutics
  • Adicet Bio
  • Adimab
  • Advanced BioScience Laboratories
  • Advent Bioservices
  • Adverum Biotechnologies
  • Aeon Therapeutics (Shanghai)
  • AFG Private Equity
  • Affiliated Hospital to Academy of Military Medical Sciences
  • AgenTus Therapeutics
  • Agreen Biotech
  • AGF Private Equity
  • AJU IB Investment
  • Aokai Biotech
  • Akron Biotech
  • Alaska Permanent Fund
  • Albert Einstein College of Medicine
  • Alexandria Venture Investments
  • Allergan
  • Alta Partners
  • Alpine Immune Sciences
  • Altor BioScience
  • Amsterdam BioTherapeutics Unit
  • Amgen
  • Anhui Kedgene Biotechnology
  • Anhui Provincial Hospital
  • Antagene
  • Anterogen
  • apceth Biopharma
  • Aquilo Capital Management
  • ARBELE
  • ARCH Venture Partners
  • Argos Therapeutics
  • ARIAD Pharmaceuticals
  • Arix Bioscience
  • Astellas Pharma
  • AstraZeneca
  • Asymptote
  • Atara Biotherapeutics
  • AT Impf
  • Atlantic Bio GMP
  • Atlas Venture
  • Atreca
  • Aurora Biopharma
  • Autolus
  • Avacta
  • AVG Ventures
  • BankInvest Biomedical Venture
  • Batavia Biosciences
  • Bavarian Nordic
  • Baxalta
  • Bayer
  • Baylor College of Medicine
  • Beijing Biohealthcare Biotechnology
  • Beijing Doing Biomedical
  • Beijing Genomics Institute
  • Beijing Immunochina Medical Science and Technology
  • Beijing Sanwater Biological Technology
  • Beijing You’an Hospital
  • Bellicum Pharmaceuticals
  • Beth Israel Deaconess Medical Center
  • Bezos Expeditions
  • Bill & Melinda Gates Foundation
  • BioAtla
  • Bio Elpida
  • Biogen
  • BioLife Solutions
  • Biomedical Catalyst
  • BioNTech Innovative Manufacturing Services
  • bluebird bio
  • Boehringer Ingelheim
  • Brace Pharma Capital
  • Brammer Bio
  • Broadfin Capital
  • Broad Institute
  • Bristol-Myers Squibb
  • Cabaret Biotech
  • Caladrius Biosciences
  • California Institute for Regenerative Medicine
  • Cancer Research UK
  • Cancer Prevention Research Institute of Texas
  • Captain T Cell
  • Cardiff University
  • Cartherics
  • Caribou Biosciences
  • Carina Biotech
  • CARsgen Therapeutics
  • Casdin Capital
  • Casebia Therapeutics
  • Cell Biotech
  • Celdara Medical
  • Cellectis
  • Cell Design Labs
  • Celgene
  • Cell and Gene Therapy Catapult
  • Cellenkos
  • Cell Medica
  • Cellular Biomedicine Group
  • CELLforCURE
  • Cell Therapies
  • Cellular Therapeutics
  • Celyad
  • Center for Cell and Gene Therapy
  • Center for Cell Manufacturing Ireland, NUI Galway
  • Center for Research in Transplantation and Immunology
  • Changhai Hospital
  • CHDI Foundation
  • Chengdu MedGenCell
  • Chiesi Farmaceutici
  • Children's Hospital of Philadelphia
  • Children's Mercy Hospital
  • Children's Oncology Group
  • Children's Research Institute
  • Chinese Academy of Sciences
  • Chinese PLA General Hospital
  • Christie NHS Foundation Trust
  • Clough Capital Partners
  • City of Hope National Medical Center
  • Cognate BioServices
  • Columbia University
  • Cook MyoSite
  • Copenhagen University Hospital
  • Cormorant Asset Management
  • Cowen Private Investments
  • CRISPR Therapeutics
  • Cryoport
  • CureVac
  • Cystic Fibrosis Foundation Therapeutics
  • CytoLumina Technologies
  • Cytovance Biologics
  • Daiichi Sankyo
  • Dana-Farber Cancer Institute
  • Dangdai International Group
  • Dartmouth College
  • Deerfield Management
  • Delenex Therapeutics
  • Dendreon
  • dievini Hopp Biotech
  • Dongguan People's Hospital
  • Dow AgroSciences
  • DS Asset Management
  • Duke Cancer Institute
  • Easton Capital Investment Group
  • EcoR1 Capital
  • Editas Medicine
  • Eli Lilly
  • Edmond de Rothschild Investment Partners
  • Endocyte
  • ERS Genomics
  • Eutilex
  • Eureka Therapeutics
  • F1 BioVentures
  • F1 Oncology
  • F2 Ventures
  • Fate Therapeutics
  • FetoLumina Technologies
  • FGP Capital
  • Financière IDAT
  • Finnish Funding Agency for Technology and Innovation
  • First Affiliated Hospital of Chengdu Medical College
  • First Affiliated Hospital of Harbin Medical University
  • First Affiliated Hospital of Sun Yat-sen University
  • First Affiliated Hospital of Wenzhou Medical University
  • First Affiliated Hospital of Zhejiang University
  • First People's Hospital of Foshan
  • F-Prime Capital
  • Five Prime Therapeutics
  • Flagship Pioneering
  • Forbion Capital Partners
  • Fondazione Telethon and Ospedale San Raffaele
  • Foresite Capital
  • Forevertek Biotechnology
  • Formula Pharmaceuticals
  • Fosun Pharmaceutical
  • Fortress Biotech
  • Franklin Templeton Investments
  • Fred Hutchinson Cancer Research Center
  • Fraunhofer Institute for Cell Therapy and Immunology
  • Friedreich’s Ataxia Research Alliance
  • Fuda Cancer Hospital
  • Fudan University
  • Fujian Medical University
  • GammaCell Bio-Technologies
  • GammaDelta Therapeutics
  • Gadeta
  • Gene and Cell Therapy Lab
  • GE Healthcare Life Sciences
  • Ghent University Hospital
  • GigaGen
  • Gilead Sciences
  • GlaxoSmithKline
  • G.N. Tech Venture Capital
  • Google Ventures
  • Green Cross Cell
  • Guangzhou Eighth People's Hospital
  • Guangzhou First People's Hospital
  • Guangzhou Xiangxue Pharmaceutical
  • Guangzhou YiYang Biological Technology
  • Guangdong Zhaotai InVivo Biomedicine
  • Guy's and St Thomas' NHS Foundation Trust
  • Hadassah Medical Center
  • Hangzhou Cancer Hospital
  • Harbin Medical University
  • Harvard University
  • Hebei Senlang Biotechnology
  • Henan Cancer Hospital
  • HengRui YuanZheng Bio-Technology
  • Herlev Hospital
  • Hitachi Chemical Advanced Therapeutics Solutions
  • H. Lee Moffitt Cancer Center and Research Institute
  • Howard Hughes Medical Institute
  • Human Stem Cells Institute
  • Hunan Zhaotai Yongren Medical Innovation
  • iCarTAB BioMed
  • iCell Gene Therapeutics
  • Immatics Biotechnologies
  • Immunocore
  • Immune Therapeutics
  • Immunovative Therapies
  • Imperial College London
  • Imperial Innovations Group
  • Innovate UK
  • Innovative Cellular Therapeutics
  • Innovative Genomins Institute
  • Intellia Therapeutics
  • Intrexon
  • Institut Curie
  • Institut Pasteur
  • Boston Children's Hospital
  • Instituto de Salud Carlos III
  • Invesco Perpetual
  • Iovance Biotherapeutics
  • Iowa State University Research Foundation
  • Janus Capital Management
  • Janssen Biotech
  • Japan Science and Technology Agency
  • Jazz Pharmaceuticals
  • JCR Pharmaceuticals
  • Jennison Associates
  • Jiangsu Cancer Hospital
  • JIC GenesisFountain Healthcare Ventures
  • John Goldman Centre for Cellular Therapy
  • Johns Hopkins University
  • Jolly Innovation Ventures
  • Jonsson Comprehensive Cancer Center
  • Juno Therapeutics
  • JW Biotechnology
  • Kaitai Capital
  • Karolinska University Hospital
  • KBI Biopharma
  • Keio University
  • Khosla Ventures
  • King's College London
  • Kite Pharma
  • Kolon Investment
  • KTB Ventures
  • Legend Capital
  • Leiden University Medical Center
  • Leucid Bio
  • Lexicon Pharmaceuticals
  • Life Technologies
  • Lifeline Ventures
  • Lilly Asia Ventures
  • Lion TCR
  • Living Pharmaceticals
  • Lonza
  • Loyola University
  • Lübeck Institute of Experimental Dermatology
  • MabQuest
  • Malin
  • Marino Biotechnology
  • MaSTherCell
  • Massachusetts General Hospital Cancer Center
  • Matrix Capital Management
  • MaxCyte
  • Max Delbrück Center for Molecular Medicine in the Helmholtz Association
  • MD Anderson Cancer Center
  • Medarex
  • Medical College of Wisconsin
  • Medicxi Ventures
  • Medigene
  • MEDINET
  • MedImmune
  • Medpost Urgent Care
  • Memorial Sloan Kettering Cancer Center
  • Merck
  • Merck Serono
  • Merlin Nexus
  • Mie University
  • Millennium Pharmaceuticals
  • Miltenyi Biotec
  • MingJu Therapeutics (Shanghai)
  • Molecular and Cellular Therapeutics
  • MolMed
  • MPM Capital
  • Mustang Bio
  • Nanjing Children's Hospital
  • Nanjing Legend Biotech
  • Nantes University Hospital
  • NantKwest
  • National Cancer Institute
  • National Heart, Lung, and Blood Institute
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health
  • National University of Singapore
  • Navy General Hospital (Beijing)
  • NCL Innovation
  • Nextech Invest
  • New Enterprise Associates
  • New Leaf Venture Partners
  • New River Management
  • NewVa Capital Partners
  • New York Medical College
  • Ningbo Cancer Hospital
  • Nikon CeLL innovation
  • Nipro
  • Noile-Immune Biotech
  • Novartis
  • Novo Ventures
  • Oaktree Capital Management
  • ODYSSEE Venture
  • Omega Funds
  • Oncodesign
  • OncoTracker
  • OnCyte
  • Ono Pharmaceutical
  • Onyx Pharmaceuticals
  • Opexa Therapeutics
  • Opus Bio
  • OrbiMed HealthCare Fund Management
  • Ospedale Pediatrico Bambino Gesù
  • Oxford BioMedica
  • Oxford MEStar
  • Partners Innovation Fund
  • Peking University
  • Perceptive Advisors
  • Peter MacCallum Cancer Centre
  • Perceptive Advisors
  • PersonGen BioTherapeutics (Suzhou)
  • Pfizer
  • PharmaCell
  • Pharmicell
  • Pinze Lifetechnology
  • Polaris Partners
  • PolyBioCept
  • Pontifax
  • Poseida Therapeutics
  • Praxis Pharmaceutical
  • Precision BioSciences
  • Precision Genome Engineering
  • Princess Margaret Cancer Centre
  • Progenitor Cell Therapy
  • ProMab Biotechnologies
  • Puma Biotechnology
  • Quogue Capital
  • RA Capital Management
  • Ramius Capital Group
  • Rayne Cell Therapy Suite
  • RedoxTherapeis
  • Redmile Group
  • Relieve Genetics
  • Regeneron Pharmaceuticals
  • Remeditex Ventures
  • Renji Hospital
  • Renmin Hospital of Wuhan University
  • Ridgeback Capital Management
  • Roche
  • Rockland Immunochemicals
  • Roger Williams Medical Center
  • RoslinCT
  • Royal Adelaide Hospital Cancer Centre
  • Roswell Park Comprehensive Cancer Center
  • RXi Pharmaceuticals
  • Sabby Management
  • Sangamo Therapeutics
  • Sanofi-Genzyme BioVentures
  • San Raffaele Hospital
  • Scottish National Blood Transfusion Service
  • Scottish Investment Bank
  • Seattle Genetics
  • Seattle Children's Hospital
  • Second Affiliated Hospital of Guangzhou Medical University
  • Sectoral Asset Management
  • Second Military Medical University
  • Second Xiangya Hospital of Central South University
  • Servier
  • Shanghai Bioray Laboratory
  • Shanghai Changzheng Hospital
  • Shanghai Cell Therapy Engineering Technology Research Center
  • Shanghai Chest Hospital
  • Shanghai Children's Medical Center
  • Shanghai GeneChem
  • Shanghai General Hospital
  • Shanghai Houchao Biotechnology
  • Shanghai Jiao Tong University School of Medicine
  • Shanghai Longyao Biotechnology
  • Shanghai Sunway Biotech
  • Shanghai Tongji Hospital
  • Shanghai Unicar-Therapy Bio-medicine Technology
  • Sheba Medical Center
  • ShengJing360.com
  • Shenzhen BinDeBio
  • Shenzhen Geno-immune Medical Institute
  • Shenzhen Hornetcorn Biotechnology
  • Shenzhen Institute for Innovation and Translational Medicine
  • Shenzhen Second People's Hospital
  • Shenzhen Sibiono GeneTech
  • Shire International
  • Sidney Kimmel Comprehensive Cancer Center
  • Sigma-Aldrich
  • Shionogi
  • Sichuan University
  • Sinobioway Cell Therapy
  • Sinobioway Group
  • SNU Bio Angel
  • Southwest General Health Center
  • Sorrento Therapeutics
  • Spark Therapeutics
  • Square 1 Bank
  • Stage Cell Therapeutics
  • Stanford University
  • St. George's Hospital
  • St. Jude Children’s Research Hospital
  • SOTIO
  • StrideBio
  • SR One
  • SunTerra Capital
  • Sun Yat-sen University
  • Syncona
  • SyndicateRoom
  • Tactiva Therapeutics
  • Takeda Pharmaceutical
  • Takara Bio
  • Targazyme
  • Target ALS Foundation
  • TC BioPharm
  • T-Cell Factory
  • TCR2 Therapeutics
  • Tel Aviv Sourasky Medical Center
  • TeneoBio
  • Tesaro
  • Tessa Therapeutics
  • Tethys Health Ventures
  • Terumo Medical
  • Nanjing Drum Tower Hospital
  • Beijing Pregene Science and Technology Company
  • The First Affiliated Hospital of Guangdong Pharmaceutical University
  • The First Affiliated Hospital of Guangzhou Medical University
  • The First Affiliated Hospital of Soochow University
  • The First People's Hospital of Yunnan
  • The First People's Hospital of Lianyungang
  • Thiel Capital
  • Netherlands Cancer Institute
  • The Ohio State University Comprehensive Cancer Center
  • The Pregene (ShenZhen) Biotechnology Company
  • Theravectys
  • Henan University of Traditional Chinese Medicine
  • Texas Emerging Technology Fund
  • Thermo Fisher Scientific
  • The Wistar Institute
  • Third Military Medical University
  • Third Rock Ventures
  • Third Security
  • Three Arch Opportunity Fund
  • TILT Biotherapeutics
  • Tianjin Medical University Cancer Institute and Hospital
  • TiGenix
  • TissueGene-C
  • Tmunity Therapeutics
  • TNK Therapeutics
  • Tongji University School of Medicine
  • Touchstone Innovations
  • TRACT Therapeutics
  • TrakCel
  • Transgene
  • Transposagen Biopharmaceuticals
  • Triumvira Immunologics
  • T. Rowe Price Associates
  • TVAX Biomedical
  • TVM Capital
  • Two Blades Foundation
  • Txcell
  • UNC Lineberger Comprehensive Cancer Center
  • Union Stem Cell & Gene Engineering
  • Universal Cells
  • University College London
  • University Health Network, Toronto
  • University of Birmingham
  • University of British Columbia
  • University of California
  • University of Florida
  • University of Lausanne
  • University Medical Center Utrecht
  • University of Milano-Bicocca
  • University of Minnesota
  • University of Pennsylvania
  • University of Sydney
  • University of Texas
  • University of Zurich
  • Uppsala University
  • Unum Therapeutics
  • Utrecht Holdings
  • Vaccinogen
  • Valeant Pharmaceuticals
  • Vecura
  • Venrock
  • Versant Ventures
  • Vertex Pharmaceuticals
  • VGXI
  • Vical
  • Viking Global Investors
  • ViroMed
  • Vitruvian Networks
  • Vor Biopharma
  • Washington University
  • Weill Cornell Medical College
  • Wellcome Trust
  • Wellington Capital Management
  • WindMIL Therapeutics
  • Woodford Investment Management
  • Wuhan Union Hospital
  • Wuhan Sian Medical Technology
  • WuXi AppTec
  • X-Body
  • Xinqiao Hospital of Chongqing
  • Xijing Hospital
  • Xuzhou Medical University
  • Yale University
  • Zelluna Immunotherapy
  • Zhejiang Huahai Pharmaceutical
  • Zhejiang University
  • Zhujiang Hospital
  • ZIOPHARM Oncology
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll